Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
02/2012 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions February patent applications/inventions, industry category 02/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
02/23/2012 > 153 patent applications in 123 patent subcategories. patent applications/inventions, industry category

20120046217 - Tnf-alpha antagonists containing igfbp5: The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and... Agent: Sungkyunkwan University Foundation For Corporate Collaboration

20120046218 - Glycosaminoglycan-antagonising mcp-i mutants and methods of using same: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.... Agent: Protaffin Biotechnologie Ag

20120046219 - Melanocortin receptor-specific peptides: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases,... Agent: Astrazeneca Ab

20120046220 - Phospholipid depot: The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from... Agent:

20120046221 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent:

20120046222 - N-terminus conformationally constrained glp-1 receptor agonist compounds: The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce a β-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce... Agent: Amylin Pharmaceuticals, Inc.

20120046223 - Exogenously triggered controlled release materials and uses thereof: The disclosure provides cross-linked materials that include multivalent cross-linking agents that bind an exogenous target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, where in the two or more affinity ligands compete with the exogenous target molecule for binding with the cross-linking... Agent:

20120046224 - Treatment of diabetes and metabolic syndrome: Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels.... Agent: Nordic Bioscience A/s

20120046225 - Stable glucagon formulations for the treatment of hypoglycemia: The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in... Agent: Xeris Pharmaceuticals, Inc.

20120046226 - Combined treatment of multiple sclerosis: The invention concerns a novel treatment multiple sclerosis, based on induced anaemia, followed by administration of an erythropoiesis-stimulating agent (ESA). In a preferred embodiment, the ESA is darbopoietin alpha, CERA or Hematide. The anaemia is induced by successive bloodlettings or by administration of an iron chelator, such as deferiprone, deferoxamine,... Agent: Assis-tance Publique - Hopitaux De Paris

20120046227 - Designer osteogenic proteins: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological... Agent: Wyeth LLC

20120046228 - Methods for modulating ovulation: The present invention relates to methods and reagents for modulating ovulation in humans and non-human animals.... Agent: University Of Medicine And Dentistry Of New Jersey

20120046229 - Modified relaxin polypeptides and their uses: Modified relaxin polypeptides and their uses thereof are provided... Agent: Ambrx, Inc.

20120046230 - Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.... Agent: Millennium Pharmaceuticals, Inc.

20120046231 - Composition and process for synthesizing polymerized human serum albumin for applications in transfusion medicine: Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally... Agent:

20120046232 - Compositions and methods for reducing relapse of addictive behavior: Disclosed are methods and compositions comprising mGluR modulators and procysteine drugs. The methods and compositions can be used to treat subjects with prior addiction in order to reduce drug use, drug seeking or relapse.... Agent: Medical University Of South Carolina

20120046233 - Mutations in the lnk gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies: Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid... Agent:

20120046234 - Therapeutic compounds: The invention provides compounds of formula I, II, and III as defined herein, as well as salts thereof. The compounds may have activity as anti-proliferative agents.... Agent:

20120046235 - Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation: Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to... Agent:

20120046236 - Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tristetraproline (TTP), in particular, by targeting natural antisense polynucleotides of Tristetraproline (TTP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression... Agent: Opko Curna LLC

20120046237 - Compositions for protection against superficial vasodilator flush syndrome, and methods of use: Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric traction, serotonin, post-menopause, alcohol, monosodium glutamate, mastocytosis, atopic dermatitis, food-allergy or food intolerance, and mast cell activation syndrome, or against individual symptoms of SVFS, superficial vasodilation, feeling of warmth, itching (pruritus) and hives, comprising a flavonoid compound of the... Agent:

20120046238 - Coumarin compounds and their use for treating viral infection: m

20120046239 - Application of american ginseng to enhance neurocognitive function: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.... Agent: Naturex S.a.

20120046240 - Method of producing hydroxyalkyl starch derivatives: The present invention relates to methods of producing hydroxyalkyl starch (HAS) derivatives having a structure according to formula (I) comprising reacting HAS of formula (I) at its optionally oxidized reducing end or a HAS derivative, obtainable by reacting HAS of formula (I) at its optionally oxidized reducing end with a... Agent:

20120046340 - Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles: The present invention relates to compositions of virus-like particles for the introduction of RNA-interference (RNAi-) inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with RNAi-inducing molecules. The present invention furthermore relates to methods for a diagnosis, prevention and/or treatment of... Agent:

20120046341 - Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases: The invention provides novel FUS/TLS nucleic acids and proteins that comprise one or more genetic markers (for example, single nucleotide polymorphisms) and methods of use thereof including methods relating to the diagnosis of ALS or other related motor neuron disease by virtue of the presence of the mutant FUS/TLS sequence(s).... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20120046343 - Multi-targeting short interfering rnas: The present invention relates to novel short interfering RNA (siRNA) molecules that are multi-targeted. More specifically, the present invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of micro-RNA (miRNA) molecules. In... Agent: City Of Hope

20120046339 - Novel chorismate mutase gene from the potato cyst nematode globodera rostochiensis: The nucleotide sequence of a 992 bp region of cDNA and the nucleotide sequence of a 1973 bp (or a 1913 bp) of genomic DNA of the Gr-cm-1 gene were determined for G. rostochiensis. PCR primers and probes specific for G. rostochiensis and G. pallida were generated. PCR assays, including... Agent:

20120046342 - Oligonucleotide comprising an inosine for treating dmd: The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon... Agent: Prosensa Technologies B.v.

20120046345 - Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression... Agent: Opko Curna, LLC

20120046344 - Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in... Agent:

20120046349 - Compositions for targeting conducting airway cells comprising adeno-associated virus constructs: An artificial AAV capsid comprising a heterologous conducting airway targeting sequence is provided. The artificial AAV is useful as a targeting moiety, for delivery of heterologous molecules which are associated therewith. The artificial AAV is also useful in the generation of AAV vectors having the artificial capsid. Also described are... Agent: The Trustees Of The University Of Pennsylvania

20120046347 - Expression of apoai and variants thereof using spliceosome mediated rna trans-splicing: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing... Agent: Virxsys Corporation

20120046348 - Oligonucleotide chelate complexes: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave... Agent: Replicor Inc.

20120046346 - Sustained polypeptide expression from synthetic, modified rnas and uses thereof: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising... Agent: Immune Disease Institute, Inc.

20120046241 - Dose of ave5026 for the treatment of venous thromboembolism in patients with severe renal impairment: This invention relates to a dose of 10 mg of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment.... Agent: Sanofi

20120046242 - Molecular activators of the wnt/beta-catenin pathway: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in... Agent: University Of Washington

20120046243 - Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators: There is disclosed aminopyridine-and aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.... Agent: Syntrix Biosystems Inc.

20120046244 - Dual functioning ionic liquids and salts thereof: Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.... Agent: Monash University

20120046245 - Compositions and methods for inhibition of the jak pathway: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals, Inc.

20120046246 - Methods for treating osteoclast-related disease, compounds and compositions thereof: This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for such uses, and compositions thereof.... Agent: University Of Florida Research Foundation

20120046247 - 1,5-diphenyl-penta-1,4-dien-3-one compounds: This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.... Agent:

20120046248 - Stabilized biocidal composition: The current invention relates to a process for stabilising a phosphorus-containing compound aqueous composition, comprising the step of adding to said composition an efficient arsenic stabilizing amount of a compound selected from the group consisting of ammonia, ammonium salt, organic amino acid, peptide and polypeptide; application of the stabilized composition... Agent: Rhodia Operations

20120046249 - Methods of reducing the risk of cardiovascular disease in postmenopausal women: The present invention features materials and methods for reducing the risk of cardiovascular disease in postmenopausal or perimenopausal women. More specifically, these methods can be used in women who generally have no apparent cardiovascular disease. We describe herein methods of administering non-antibacterial tetracycline or a sub-antimicrobial amount of antibacterial tetracyclines... Agent: The Research Foundation Of State University Of New York

20120046250 - Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell: Provided herein are novel compounds, pharmaceutical compositions for use, inter alia, in methods of reducing Wnt-mediated effects and treating cancer.... Agent: Stemsynergy Therapeutics, Inc

20120046251 - Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing: The invention discloses methods of using cis-epoxyeicosantrienoic acids (“EETs”), inhibitors of soluble epoxide hydrolase (“sEH”), or a combination of an EET and an inhibitor of sEH, to reduce or prevent niacin-induced cutaneous vasodilation (“flushing”) in subjects suffering from this undesirable side effect of receiving therapeutic amounts of niacin.... Agent: The Regents Of The University Of California

20120046252 - Calcium formate for use as a dietary supplement: A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.... Agent:

20120046253 - Stable pharmacologically active compositions including vitamin d containing and corticosteroid compounds with low ph compatibility: Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of... Agent: Teva Pharmaceutical Industries Ltd.

20120046254 - Dispersion of phytosterols: The invention relates to a method for the production of highly stable aqueous dispersions of phytosterols, phytostanols and derivatives thereof, which allows the use of a wide range of emulsifiers in relatively small concentrations in relation to the phytosterols and which allows the preparation of dispersions with high concentrations of... Agent:

20120046259 - Composition comprising an antibiotic and a corticosteroid: This invention relates to compositions (e.g., otic compositions) comprising an antibiotic (generally a quinolone or naphthyridinone), corticosteroid, and organic acid (generally a fatty acid). This invention also relates to treatment methods using such a composition, uses of such a composition to make medicaments, and therapeutic kits comprising such a composition.... Agent:

20120046256 - Lipolytic methods for regional adiposity comprising salmeterol or formoterol: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments... Agent: Lithera, Inc.

20120046257 - Methods for administration and formulations for the treatment of regional adipose tissue: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable... Agent: Lithera, Inc.

20120046255 - Non-steroidal compounds: The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them. A representative example of these compounds is... Agent: The University Of Melbourne Of Royal Parade Parkville

20120046258 - Novel crystalline pharmaceutical product: e

20120046260 - Methods and devices for delivery of compositions to conduits: The present invention comprises systems, methods and devices for the delivery of visualizable or treatment compositions or therapeutic agents comprising device elements for diagnosis and/or treatment of conduits. A delivery system comprising an introducer shaft having at least one exit port and at least one delivery catheter for placement of... Agent: Femasys Inc.

20120046261 - Compositions and methods for diagnosing and preventing spontaneous preterm birth: Disclosed herein are compositions and methods of identifying a subject at risk for preterm birth and selecting effective therapies for preventing preterm birth in the subject. The disclosed methods generally involve determining the identity of one or more nucleotides in the progesterone receptor (PR) gene of the subject.... Agent: University Of Utah Research Foundation

20120046262 - Megestrol acetate products, method of manufacture, and method of use: Disclosed herein is a method of using megestrol acetate. In one embodiment, the method comprises informing a user that megestrol acetate is metabolized by a cytochrome p450 isozyme. In another embodiment, the method comprises obtaining megestrol acetate from a container associated with published material providing information is metabolized by a... Agent: Mutual Pharmaceutical Company, Inc.

20120046263 - Method to alter sex ratios in avian offspring: The present invention includes methods of influencing the sex chromosome ovulated by a female bird and altering the sex ratio in avian offspring by altering the exposure of an ovulating female bird to one or more stress hormones. In some aspects, the method includes exposing an avian female to a... Agent: Univeristy Of Georgia Research

20120046264 - Commercial scale production methods for transdermal hormone formulations: Methods for commercial production of transdermal formulations comprising a hormone compound are provided. In particular, methods for commercial scale production under an inert atmosphere of a transdermal formulation comprising a therapeutically effective amount of a hormone, preferably a testosterone compound, useful for the treatment of hypoactive sexual desire disorder (HSDD)... Agent: Biosante Pharmaceuticals, Inc.

20120046265 - Use of ergosta-7,22-dien-3beta-ol in the treatment of cancer: A use of an isolated and purified form of ergosta-7,22-dien-3β-ol in the treatment of cancer is provided.... Agent: Vita Green Biotechnology Co. Limited

20120046267 - 7-aminofuropyridine derivatives: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.... Agent: Osi Pharmaceuticals, Inc.

20120046268 - Substituted piperidines as par-1 antagonists: The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumour disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120046266 - Resorcinol derivatives as hsp90 inhibitors: The present invention relates to substituted resorcinol derivatives which inhibit the activity of Heat Shock Protein HSP90. The compounds of the invention are therefore useful in treating proliferative diseases such as cancer and neurodegenerative diseases. The present invention also provides processes for preparing these compounds, pharmaceutical compositions comprising them, methods... Agent: Nerviano Medical Sciences S.r.l.

20120046269 - Novel amino azaheterocyclic carboxamides: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.... Agent: Merck Patent Gmbh

20120046270 - Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, X4, X5, Q, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations... Agent: Boehringer Ingelheim International Gmbh

20120046271 - 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin: e

20120046272 - Novel therapeutic compounds: that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted... Agent: Grunenthal Gmbh

20120046274 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors: a

20120046275 - Cytoskeletal active rho kinase inhibitor compounds, composition and use: The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated... Agent:

20120046273 - Compounds and compositions for cognition-enhancement, methods of making, and methods of treating: Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided... Agent: Mithridion, Inc.

20120046276 - Tuberculosis treatment using pleuromutilin derivatives: A method of preventing or treating diseases caused by Mycobacterium, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.... Agent: Nabriva Therapeutics Ag

20120046277 - Benzofuran derivatives: The present invention provides a compound represented by the following formula (I): wherein: Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted bromopiperazine ring; R1 and R2 are the same or different from each other, and represent a hydrogen atom or optionally... Agent:

20120046278 - Thiazolopyrimidine modulators as immunosuppressive agents: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present... Agent: Katholieke Universiteit Leuven, K.u.leuven R&d

20120046279 - Oligomer-phenothiazine conjugates: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.... Agent: Nektar Therapeutics

20120046280 - Novel heteropyrrole analogs acting on cannabinoid receptors: Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or CB2 cannabinoid receptors. Aspects disclose hetero pyrrole analogs acting as CB1 and/or CB 1 receptor antagonists, having selectivity for the CB 1 or CB2 receptor, acting as neutral antagonists,... Agent:

20120046281 - Rifalazil compositions and therapeutic regimens: The invention features low-dosage rifalazil compositions and therapeutic regimens which are useful for the treatment of bacterial infections.... Agent: Activbiotics Pharma, LLC.

20120046282 - Methods and compounds for antimicrobial intervention: The present invention provides Wall Teichoic Acid biosynthesis inhibitors such as compound 1835F03 (targocil) and related synthetic analogs. The invention also provides pharmaceutical compositions thereof and methods for treating bacterial infection and the suppression of growth of bacterial cells by administering a Wall Teichoic Acid biosynthesis inhibitor. The invention is... Agent: President And Fellows Of Harvard College

20120046283 - Compounds for treating neuropsychiatric conditions: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of neuropsychiatric conditions.... Agent: Afraxis Inc.

20120046285 - Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.... Agent: Alcon Research, Ltd.

20120046286 - Novel compounds: e

20120046284 - Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof: which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, processes for the stereoselective preparation of this compound, particularly for the inhalation of suitable pharmaceutical formulations and their use for the treatment of diseases, particularly tumour diseases, benign prostatic hyperplasia and diseases of the... Agent: Boehringer Ingelheim International Gmbh

20120046287 - Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them: i

20120046288 - Hydrazonamide compounds that modulate hsp90 activity: The present invention relates to substituted hydrazonamide compounds. The invention further relates to methods of inhibiting the activity of Hsρ90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted hydrazonamide compound... Agent: Synta Pharmacueticals Corp.

20120046289 - Pyridazine carboxamide orexin receptor antagonists: The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent:

20120046290 - Inhibition of p38 kinase activity using substituted heterocyclic ureas: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.... Agent:

20120046292 - Diacylethylenediamine compound: The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of... Agent: Astellas Pharma Inc.

20120046291 - Extended triterpene derivatives: The present invention concerns novel pharmaceutically active triterpene derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are derivatives of... Agent:

20120046293 - Renin inhibitors: e

20120046294 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20120046295 - Compounds useful as inhibitors of atr kinase: e

20120046296 - Palatable ductile chewable veterinary composition: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like... Agent:

20120046297 - Crystalization of pharmaceutical compounds: Novel crystalline forms of tadalafil suitable for pharmaceutical compositions in drug delivery systems for humans.... Agent:

20120046298 - Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics: v

20120046299 - Method of treating arrhythmias: Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects.... Agent: Gilead Sciences, Inc.

20120046300 - Quinazoline derivatives as angiogenesis inhibitors: wherein: ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms selected independently from O, N and S; is —O— —NH— or —S—; is 0, 1,... Agent:

20120046301 - Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor: Substituted cyclic carboxamide and urea compounds, a process for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for the treatment and/or inhibition of pain and other conditions mediated by the vanilloid receptor 1.... Agent: Gruenenthal Gmbh

20120046302 - Methods of treating cns disorders: The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.... Agent:

20120046303 - Benzimidazole poly(adp ribose)polymerase inhibitors: Compounds which inhibit the activity of poly(ADP-ribose)polymerase (PARP), compositions containing the compounds and methods of treating diseases using them are disclosed.... Agent: Abbott Laboratories

20120046304 - Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation: m

20120046305 - Methods and compositions for treating respiratory disorders: Compounds and compositions for treating disorders related to TRPA1 are described herein.... Agent:

20120046306 - Substituted heteroaryl spiropyrrolidine mdm2 antagonists: m

20120046307 - Allosteric protein kinase modulators: The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to... Agent: Universitaet Des Saarlandes

20120046308 - Novel alpha-phenoxybenzeneacetic acid derivative and pharmaceutical preparation comprising same: An α-phenoxybenzeneacetic acid derivative represented by general formula (I), which has both an angiotensin II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, metabolic syndrome or the like, a salt of the derivative, or a solvate of the derivative... Agent: Kowa Company, Ltd.

20120046309 - Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis: The present invention relates to the identification of inventive pyrimidine-2,4,6-triones (PYT compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the inventive PYT compounds.... Agent: Cambria Pharmaceuticals, Inc.

20120046310 - Compositions for delivering highly water soluble drugs: The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.... Agent: Adventrx Pharmaceuticals, Inc.

20120046311 - Chemokine receptor antagonists and methods of use thereof: e

20120046312 - 3-substituted propanamine compounds:

20120046313 - Siloxane polymer containing tethered fluoroquinolone: A polymer that is a polysiloxane polymer has fluoroquinolone antibiotic groups, or pharmaceutically acceptable salts thereof, attached via linkers. The linkers may be hydrolytically labile thereby providing a manner of releasing the fluoroquinolone antibiotic from the polymer.... Agent: Ndsu Research Foundation

20120046314 - Nitroxides for use in treating or preventing neoplastic disease: Pharmaceutical compositions are provided that are useful in treating or preventing neoplastic disease, such as cancer. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cancer. Methods are also... Agent: Mitos, Inc.

20120046315 - Intermediate and oral administrative formats containing lenalidomide: The invention relates to non-crystalline lenalidomide in the form of a storage-stable intermediate, i.e. preferably amorphous lenalidomide together with a surface stabiliser in the form of a stable intermediate or a storage-stable intermediate, containing lenalidomide and matrix material, wherein the lenalidomide is present in the form of a solid solution... Agent:

20120046316 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Celgene Corporation

20120046317 - Novel heterocyclic compounds: The present invention relates to a new class of heterocyclic compounds and pharmaceutically acceptable salts thereof, process for preparing the same, pharmaceutical composition containing these compounds and to their use in treatment of diseases caused due to formation and accumulation of AGEs (Advanced Glycation end products). The compounds of the... Agent:

20120046318 - Methods and compositions for treating internal and external hemorrhoids: The present invention relates to compositions and methods for treatment of internal and/or external hemorrhoids, wherein the treatment includes topically administering to a subject a composition comprising from 0.3% to 0.7% of S-2′-[2-(1-methyl-2-piperidyl)ethyl]cinnamanilide, wherein the S-2′-[2-(1-methyl-2-piperidyl)ethyl]cinnamanilide not only treats the hemorrhoidal symptoms but delays or inhibits the recurrence of hemorrhoids... Agent:

20120046320 - Beta- and gamma-diketones and gamma-hydroxyketones as wnt/beta-catenin signaling pathway activators: The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related... Agent: Wintherix, LLC

20120046319 - Process for the preparation of enantiomerically enriched proton pump inhibitors: The invention discloses a process for the preparation of compounds having structures typical for proton pump inhibitors in enantiomerically enriched form by using particular metal catalysts in an enantioselective oxidation step. Also disclosed are useful further processes and pure intermediate and subsequently final products.... Agent:

20120046321 - Methods of treating atrial fibrillation with p38 inhibitor compounds: The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).... Agent: Intermune, Inc.

20120046322 - Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA... Agent: Intrexon Corporation

20120046323 - Use of succinate dehydrogenase inhibitors and/or respiratory chain complex iii inhibitors for improving the ratio of harmful to beneficial microorganisms: The present invention relates to the use of succinate dehydrogenase inhibitors and/or complex III inhibitors for controlling undesired fungal pathogens and simultaneously improving the ratio of harmful to beneficial microorganisms in crops and to a method for treating crops or parts of crops for controlling undesired fungal pathogens and simultaneously... Agent: Bayer Cropscience Ag

20120046324 - Small molecule inhibitors of kynurenine-3-monooxygenase: The present invention relates to compounds of Formula I below and their tautomers or pharmaceutically acceptable salts, compositions and methods of uses thereof.... Agent: Under The Will Of J. David Gladstone

20120046325 - Isoxazoline compounds having mif antagonist activity: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses,... Agent: Cytokine Pharmasciences, Inc.

20120046326 - Drug containing benzophenone derivative or its salt: wherein the each substituent is as defined in the specification, or salts thereof have suppressive effect on RANKL production, suppressive effect on OPG reduction and inhibitory effects on differentiation/activation of osteoclasts, and are extremely useful for treating, for example therapy and/or prevention, of various diseases in which differentiation/activation of osteoclast... Agent: Toyama Chemical Co., Ltd.

20120046327 - Method for inhibiting the induction and formation of osteoclasts: Methods for (i) inhibiting the induction and formation of osteoclasts, (ii) inhibiting RANKL expression in osteoblasts, (ii) inhibiting the activation of osteoclasts and (iv) inhibiting a decrease in bone density by administering to a warm-blooded animal in need thereof a pharmacologically effective amount of a compound selected from the group... Agent: Daiichi Sankyo Company, Limited

20120046328 - Chemically stable dispersions of prothioconazole and processes for preparing them: Chemically stable aqueous dispersions of prothioconazole and processes for preparing them are provided. The dispersions comprise prothioconazole present in an aqueous medium, and a sulfur-containing compound present in an amount effective to render the dispersion chemically stable.... Agent:

20120046329 - Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof: Disclosed herein are compositions and methods relating to modulators of Nod-like Receptors NOD1 (NLRC1) and NOD2 (NLRC2) signaling. Further provided are methods of identifying modulators of Nod-like Receptors NOD1 and NOD2 activity. Further provided are compositions and methods for treating or preventing inflammation, including diseases associated with inflammation such as... Agent: Sanford-burnham Medical Research Institute

20120046330 - Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d] [1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof: A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis.... Agent: Vertex Pharmaceuticals Incorporated

20120046331 - Antifungal agents and uses thereof: This invention relates to new antifungal agents, compositions thereof, and methods for inhibiting the growth of fungi involved in infection and disease of keratinized tissue, such as onychomycosis. The invention also relates to new antifungal agents, compositions thereof, and methods for treating and/or preventing fungal infection and/or disease of keratinized... Agent:

20120046332 - Compositions and methods for treating corneal haze: Disclosed herein are compositions and methods for treating corneal haze. Compositions and methods of use comprise therapeutically effective amounts of compounds that agonize the EP2 and/or EP4 receptor. Administration of the disclosed compounds can prevent and treat corneal haze development.... Agent: Allergan, Inc.

20120046333 - Methods and compositions of pi-3 kinase inhibitors for treating fibrosis: Methods and compositions of PI-3 kinase inhibitors and their use in inhibiting PI-3 kinase activity in mammals and the treatment of fibrosing syndromes in a subject are described herein... Agent: Oncothyreon Incorporated

20120046334 - Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer: The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present... Agent:

20120046335 - Solid states of atorvastatin potassium: Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of... Agent: Teva Pharmaceutical Industries Ltd.

20120046336 - Methods and compositions for improving cognitive function: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects... Agent: The Johns Hopkins University

20120046337 - Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing α- and β-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human β-hexosaminidase, a new target for development of... Agent: Academia Sinica

20120046338 - Fused cyclic compounds: v

20120046350 - Novel compounds, their preparation and use: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular... Agent: High Point Pharmaceuticals, LLC

20120046352 - Controlled cannabis decarboxylation: The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (Δ9-THC) and other cannabinoid medicinal substances are decarboxylated through a chemical reaction facilitated by a cofactor. The amount of medicinal cannabis decarboxylated will be directly proportional to the amount of cofactor used. Use a small... Agent:

20120046351 - Medicinal cannabis added in food: The invention is a product and a process wherein cannabinoids such as Medicinal Δ9-THC and/or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are added to a foodstuff where the medicinal cannabis is not evenly distributed throughout the foodstuff where the food stuff contains... Agent:

20120046353 - Cleistocalyx operculatus-derived compounds having inhibitory activities against avian and swine influenza viruses or novel influenza virus: The present invention relates to a Cleistocalyx operculatus-derived compound having inhibitory activity against neuraminidase and to a composition for preventing and treating diseases caused by avian and swine influenza viruses and novel influenza viruses, comprising the compound as an active ingredient.... Agent: Choong Ang Vaccine Lab.

20120046354 - Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders: A method for treating or preventing oral cavity mucosal disorders, comprising a step of providing a lozenge containing an antioxidant selected from the group of Vitamin A, Vitamin C, Vitamin E; and other ingredients and a step of placing the lozenge within the oral cavity for a period of time... Agent:

20120046355 - Inhibitors of sialidase or sialidase-like enzymes: The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of producing non-2-enonate compounds.... Agent:

20120046356 - New process for preparing diketones and medicaments: There is provided a process for the preparation of a compound of formula (III), wherein X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone. There is also provided a process for the preparation of... Agent: Cambrex Karlskoga Ab

20120046357 - Benzamide and napthamide derivatives inhibiting nuclear factor-kappa (b) - (nk-kb): e

20120046358 - Use of isothiocyanates compounds in treating prostatic diseases and skin cancer: A method for preventing and treating prostatic diseases and skin cancer using naturally or artificially synthesized isothiocyanates compounds or the derivatives or metabolites thereof.... Agent: Wuxi Jc Pharmaceutical Technology Co., Ltd.

20120046359 - Bed bug control and repellency: Control or repellency of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one compound selected from the group consisting of certain alkyl ketones and cyclic ketones wherein the total number of carbon atoms in the alkyl ketones and cyclic ketones... Agent:

20120046360 - Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the... Agent:

20120046361 - Ethyl pyruvate compositions and methods: Compositions and methods are disclosed for use of ethyl pyruvate to boost energy, endurance, or to feel good, or to lose weight. Pharmaceutical preparations having ethyl pyruvate are disclosed herein as well.... Agent: American Symbolic, LLC

20120046362 - Antiviral agent and cleansing agent: It is an object to provide an antiviral agent that can be used for persons having sensitive skin or on the face, inactivates viruses such as a norovirus and an influenza virus, and is excellent in germicidal properties. Further provided is a cleansing agent that does not lead to environmental... Agent: Shabondama Soap Co., Ltd

20120046363 - Docosahexaenoic acid for the treatment of heart failure: There is currently no completely effective treatment for heart failure. Considering the need for, and current void in the medical field for, a treatment for heart failure, the invention is drawn to treating heart failure. In particular aspects, the invention is drawn to the discovery that certain polyunsaturated fatty acids... Agent: University Of Maryland, Baltimore

20120046364 - Novel sulfonic acid-containing thyromimetics, and methods for their use: The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R1, R3 and T are as defined in the claims, that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The... Agent: Metabasis Therapeutics, Inc.

20120046365 - Method and composition for administering an nmda receptor antagonist to a subject: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... Agent: Adamas Pharmaceuticals, Inc.

20120046366 - Extractions of fixed oil and thymoquinone rich fractions (tqrf): The present invention reported that SFE is suitable for Nigella sativa seeds oil extraction and fractionation. TQRF that were produced through SFE extractions (600 bars/40° C.) and fractionations (100-200 bars/40-60° C.) possessed high level of TQ and antioxidant activity. SFE fractionation efficiently concentrates the TQ content and antioxidant activity of... Agent: Universiti Putra Malaysia

20120046367 - Essential oil composition with anti-free radical ability: Disclosed is an essential oil composition with anti-free radical ability, which includes dl-Citronellol, Eugenol, cis/trans-Citral, Eugenol Methyl Ether and Thymol. It is confirmed that the essential oil composition of the present invention has superior anti-free radical ability and anti-oxidative ability according to the indices including DPPH free radical scavenging ability,... Agent:

20120046368 - Method for purifying 3,4-dihydroxyphenylglycol (dhpg) from plant products: Process for purifying 3,4-dihydroxyphenylglycol (DHPG) from any part of the plant, from the products or by-products derived from olive trees or any other vegetable product of the families Oleaceae, Orobanchaceae, Plantaginaceae, Compositae, Lamiaceae, Acanthaceae and/or Scrophulariaceae, and which comprises 1 or more steps wherein the initial product is introduced into... Agent: Consejo Superior De Investigaciones Cientificas

20120046369 - Methods for enhancing the stability of foods, beverages, and cosmetics using natural products derived from non-allergenic proteinaceous sources: The present invention relates to compositions with effective metal chelating activity and utility as natural antioxidants in food, beverages, nutritional supplements and cosmetics. The compositions of the present invention may be prepared by enzymatically hydrolyzing hypoallergenic protein isolates derived from vegetables, for example yellow pea (Pisum sativum), and/or grains using... Agent: Kalamazoo Holdings, Inc.

  
02/16/2012 > 199 patent applications in 149 patent subcategories. patent applications/inventions, industry category

20120040884 - Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration: Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its... Agent: University Of Iowa Research Foundation

20120040885 - Analogues of neuropeptide y having at least one synthetic amino acid substitution: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino... Agent:

20120040886 - Analogues of neuropeptide y having proline substitution at position 34: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34... Agent:

20120040887 - Composition for the treatment of osteomyelitis, method for preparing the same, and method for the treatment of osteomyelitis: e

20120040888 - Anti-infective hydroxy-phenyl-benzoates and methods of use: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

20120040890 - Inhibitor of the uracil-dna glycosylase enzyme and uses thereof: The present invention relates to a protein which has the capacity to bind to and inhibit the viral uracil DNA glycosylase (UDG) enzyme and its use as a therapeutic agent; in particular, as an antiviral agent.... Agent: Consejo Superior De Investigaciones

20120040889 - Peptidomimetic macrocycles: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease.... Agent: Aileron Therapeutics Inc.

20120040891 - Hiv fusion inhibitor peptides with improved biological properties: Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide... Agent:

20120040892 - Methods and compositions for the treatment of heart failure and other disorders: Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.... Agent:

20120040893 - Modification of feeding behaviour: Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject.... Agent:

20120040894 - Mini-hepcidin peptides and methods of using thereof: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.... Agent:

20120040895 - Peptide availability: s

20120040896 - Compositions, methods and uses for modulation of brca 1: Embodiments of the present invention generally relate to methods, compositions and uses for diagnosis and treatment of cancer. Certain embodiments report methods and compositions for diagnosing and/or treating a subject having a BRCA1-related cancer or sporadic cancer. Some embodiments disclose treatments that can include, but are not limited to, modulation... Agent: The Regents Of The University Of Colorado

20120040897 - Novel derivatives of acyl cyanopyrrolidines: A compound of formula (I) or a tautomeric form, regioisomer, stereoisomer, solvate, N-oxide or pharmaceutically acceptable salts thereof; wherein ‘a’—is selected from the group consisting of substituted or unsubstituted heterocycloalkyl ring and substituted or unsubstituted carbohydrate moiety y is a member selected from —O—, —CO—, —S02-, aminoalkyl or formula (II)... Agent: Sun Pharma Advanced Research Company Ltd.

20120040898 - Pharmaceutical compositions: (B) at least one member of the group consisting of biguanides, insulin secretagogues, insulin sensitizers, insulins, dipeptidyl peptidase IV inhibitors, α-glucosidase inhibitors, and GLP-1 mimetics, has superior efficacy in preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus and yet it causes no appreciable... Agent: Taisho Pharmaceutical Co., Ltd

20120040899 - Method for treating hyperglycemia with glp-1: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1... Agent: Mannkind Corporation

20120040900 - Compositions of and methods of using ligand dimers: Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to... Agent: Massachusetts Institute Of Technology

20120040901 - Novel biomaterials, their preparation and use: wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further... Agent:

20120040902 - Method of treating dyspnea associated with acute heart failure: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.... Agent:

20120040903 - Method for treating dyspnea associated with acute heart failure: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.... Agent:

20120040904 - Boronate medicaments for preventing thrombosis during surgery: The use for the manufacture of a medicament for preventing unwanted coagulation during surgery, and particularly a Coronary Artery By pass Graft (CABG) procedure, of boronic acids of formula (I), and salts, prodrugs and prodrug salts thereof; wherein Y comprises a moiety which, together with the fragment —CH(R9)—B(OH)2, has affinity... Agent: Trigen Holdings Ag

20120040905 - Means for purifying a coagulation protein, and methods for implementing same: An affinity substrate for selectively binding a coagulation protein, includes a substrate solid on which nucleic aptamers binding specifically to the coagulation protein are immobilized.... Agent: Lfb Biotechnologies

20120040906 - Protein targets in disease: MicroRNAs have been shown to be critically involved in control of cell survival and cell death decisions. By identifying microRNAs implicated in Endoplasmic Reticulum stress-induced cardiomyocyte apoptosis, it is envisaged that protein targets involved in same can be identified through specifically selected microRNAs. The microRNAs targeted are miR-351, miR-322, miR-125,... Agent: National University Of Ireland, Galway

20120040907 - Method of use of bioactive materials: A bioactive material is made using fibroin solutions and suspensions designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce... Agent: The University Of Connecticut

20120040908 - Fracture repair promoter: Disclosed is a substance capable of promoting the repair of a fractured part in a fracture caused by an external force, fatigue or a disease. Also disclosed is a method for producing the substance. Further disclosed is a product capable of promoting the repair of a fracture, such as a... Agent: Kyushu University, National University Corp.

20120040909 - Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes: A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide... Agent: Centre National De La Recherche Scientifique Cnrs

20120040910 - Methods of preventing or treating brain diseases: The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient.... Agent:

20120040911 - Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine... Agent:

20120040912 - Proteasome-activating anti-aging peptides and compositions containing same: In addition, the present invention relates to, on the one hand, a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a cosmetically or pharmaceutically acceptable medium and, on the other hand, its utilization to prevent or treat the cutaneous signs of aging and photo-aging... Agent:

20120040913 - Methods and compositions for treating diabetes: The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes α1-antitrypsin or an α1-antitrypsin-like agent, including, but... Agent:

20120040914 - Enhancing effectiveness of glial cancer therapies: A method of enhancing the effectiveness of a chemotherapeutic agent, such as Temozolomide (TMZ), or ionizing radiation against glioblastoma is described in the present invention. The method comprises targeting putative membrane androgen receptor (termed mAR) in glioma cells to enhance the cytotoxic effects of a chemotherapeutic agent or ionizing radiation... Agent: University Of North Texas Health Science Center At Fort Worth

20120040915 - Peptides and nanoparticles for therapeutic and diagnostic applications: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.... Agent:

20120040916 - Molecular inhibitors of the wnt/beta-catenin pathway: The present invention is directed toward a method of treating a subject for a condition mediated by the Wnt/β-catenin pathway by selecting a subject with a condition mediated by the Wnt/β-catenin pathway and administering to the selected subject a compound selected from the group consisting of those set forth in... Agent: University Of Washington

20120040917 - Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease: The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching... Agent: Santaris Pharma A/s

20120040918 - Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.... Agent: Cti Bio

20120040919 - Exfoliating composition based on cream of tartar and bicarbonate: A solid exfoliating composition includes a surfactant, sodium bicarbonate, cream of tartar, and a granular exfoliant.... Agent: Cosmetic Warriors Ltd.

20120040920 - Oligosaccharide aldonic acids and their topical use: Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment... Agent:

20120040921 - Compositions and products containing s-equol, and methods for their making: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in... Agent: Australian Health & Nutrition Association Limited

20120040922 - Antibiotic macrocycle compounds and methods of manufacture and use thereof: The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically... Agent:

20120041050 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20120041051 - Compositions and methods for inhibiting expression of mig-12 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting MIDI interacting G12-like protein (MIG 12) gene, and methods of using the dsRNA to inhibit expression of MIG 12.... Agent:

20120041054 - Compositions and methods for the treatment of sepsis and other disorders involving phospholipase a2 induction: The present invention provides antisense oligomers to PLA2 to inhibit PLA2 protein expression and enzyme activity, and to treat diseases and disorders associated with induced expression of PLA2. In particular, the invention provides for the simultaneous inhibition of cPLA2 and sPLA2.... Agent:

20120041048 - Compositions and methods relating to mir-31: MicroRNA-31 (miR-31), targets of miR-31, the role of miR-31 in inhibiting tumor metastasis, and the role of miR-31 target genes in promoting tumor metastasis are disclosed.... Agent: Whitehead Institute For Biomedical Research

20120041052 - Compositions and methods to treat muscular & cardiovascular disorders: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.... Agent: Novartis Ag

20120041053 - Delivery of dsrna to arthropods: The invention is to methods of gene silencing in arthropods using dsRNA. The method is include contacting the arthropod with, and/or directly feeding the arthropod, the dsRNA to the arthropods to deliver the dsRNA to arthropod tissues. It is envisaged that the methods of the invention will have use in... Agent: Commonwealth Scientific And Industrial Research Organisation

20120041049 - Design of small-interfering rna: The present invention relates to small-interfering RNA molecules displaying an increased thermodynamic stability at the 3′ end of the antisense strand (guide strand) and the 5′ end of the sense strand (passenger strand), respectively, in comparison to the base pairing in the seed region. The siRNAs of the present invention... Agent: Riboxx Gmbh

20120041047 - Injectable pharmaceutical composition for preventing, stabilizing and/or inhibiting pathological neovascularization-related conditions: or any function conservative sequence comprising from 9 to 30 nucleotides that has 75%, 80%, 85%, 90%, 95%, more than 95%, 96%, 97%, 98%, or 99% identity compared to SEQ ID NO: 1 and that conserves the capacity of inhibiting IRS-1 gene expression as SEQ ID NO: 1, and the... Agent: Gene Signal International Sa

20120041055 - Composite polynucleic acid therapeutics: Compositions comprising therapeutic polynucleic acids and method of use. The compositions comprise one or more polynucleic acid sequences having two or more features useful for treating diseases associated with cellular proliferation or growth.... Agent:

20120041056 - Nucleic acids specifically binding with human factor vii/viia and uses thereof: A nucleic acid includes at least 15 nucleotides with a length specifically binding with the human factor VII/VIIa.... Agent: Lfb Biotechnologies

20120041057 - Synthesis and characterization of c8 analogs of c-di-gmp: The invention provides analogs cyclic diguanosine monophosphate (c-di-GMP) having different substituents at the guanine C8 position.... Agent:

20120040923 - Stable s-adenosyl-l-methionine: Stable compositions of defined non-racemic diastereomeric ratios of S-adenosyl-L-methionine, methods for their synthesis and methods for their uses are described. The compositions according to the invention are very stable and are valuable for use as active constituents in pharmaceutical compositions.... Agent:

20120040924 - Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections: The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts,... Agent: Rfs Pharma, LLC.

20120040925 - Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers: This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.... Agent:

20120040926 - Process for obtaining polysaccharides from jatoba (hymenea courbaril l) seeds, cosmetic composition comprising said polysaccharides and uses thereof: The present invention relates to a process for obtaining polysaccharides from jatoba seeds, comprising the steps of: a) seed processing (dry process); b) aqueous extraction at 1% to 5% of powder mass per volume, preferably 2% of powder mass per volume; c) precipitation with ethanol 969GL using 1 to 3... Agent:

20120040927 - Medicinal antifungal and steroid cream incorporating a biopolymer and a process to make it.: The present invention is directed to a composition for treating fungal skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antifungal active ingredient. It discloses a composition for treating fungal skin infections &... Agent: Apex Laboratories Private Limited

20120040928 - Methods and compositions for inhibiting cellular proliferation and surgical adhesion: A method for inhibiting cellular proliferation of fibroblasts and/or blioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fi- broblasts and gliomas in the mammal... Agent:

20120040929 - Food composition comprising glucosamine: The present invention relates to an orally ingestible food or pet food composition or cosmetic composition containing glucosamine generated from plant materials through a drying process for the maintenance of joint health or prevention, alleviation and/or treatment of osteoarthritis, or the improvement of the skin quality and prevention or restoration... Agent: Nestec S.a.

20120040931 - Novel organopolysiloxane and cosmetic containing the same: (each R1 independently represents a group selected from an alkyl group having 1 to 30 carbon atoms, a fluorine-substituted alkyl group having 1 to 30 carbon atoms, an aryl group having 6 to 30 carbon atoms, and an aralkyl group having 6 to 30 carbon atoms; Y represents a polyvalent... Agent: Shin-etsu Chemical Co., Ltd.

20120040930 - Tetracyclic terpene series compounds, methods for preparing same, uses thereof as medicines and pharmaceutical compounds containing same: The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.... Agent:

20120040933 - 9-(piperazinylalkyl) carbazoles as bax-modulators: piperazine compounds for use as pharmaceutically active compounds and in pharmaceutical formulations that are useful for the treatment of disorders associated with apoptosis, including neurodegenerative disorders, diseases associated with polyglutamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders, renal hypoxia, hepatitis and AIDS, where the piperazine compounds are represented by formula (I)... Agent: Applied Research Systems Ars Holding N.v.

20120040932 - Cyclic boronic acid ester derivatives and therapeutic uses thereof: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.... Agent: Rempex Pharmaceuticals, Inc.

20120040934 - Omega-3 enriched fish oil-in-water parenteral nutrition emulsions: An emulsion is provided including: an oil component and a water component, the oil component including: fish oil triglycerides in an amount of about 60% to about 90% based on the weight of the oil component; wherein the fish oil triglycerides include omega-3 fatty acids, expressed as triglycerides, in an... Agent: Stable Solutions LLC

20120040935 - Compositions useful as inhibitors of voltage-gated ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals, Inc.

20120040936 - Cyclic compound having substituted phenyl group: Low molecular weight compound exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof:... Agent: Daiichi Sankyo Company, Limited

20120040937 - Compounds for the treatment of proliferative disorders: w

20120040938 - Glucocorticoid receptor alleles and uses thereof: Provided here in are, inter alia, methods of determining whether a patient is resistant or sensitive to glucocorticoid therapy.... Agent: Shriners Hospital For Children

20120040939 - Medicinal use of 5-benzylaminosalicylic acid derivative or its salt: The present invention relates to a pharmaceutical composition for treating or preventing stress disorder, depression, anxiety disorder, comprising 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt. The present invention relates to a method for treating or preventing stress disorder, depression, anxiety disorder, comprising 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable... Agent: Neurotech Pharmaceuticals Co., Ltd.

20120040941 - 5-(2--1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases: in the form of a racemate, a stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treating, for example, a pulmonary disease or condition associated with β2 adrenergic receptor activity in a mammal, in which the compound is administered... Agent:

20120040940 - Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.... Agent:

20120040943 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma... Agent:

20120040942 - Novel bronchodilating diazaheteroaryls: The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.... Agent: Respiratorius Ab

20120040944 - medicinal cream made using mometasone furoate and chitosan and a process to make the same: The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form... Agent: Apex Laboratories Private Limited

20120040945 - Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma: Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of... Agent: Activaero Gmbh Research & Development

20120040946 - Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it: The present invention is directed to a medicinal composition for treating bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises a) a biopolymer in the form of Chitosan, b) an... Agent: Apex Laboratories Private Limited

20120040947 - Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy: e

20120040949 - Inhibitors of bruton's tyrosine kinase: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell... Agent:

20120040952 - Azetidines as histamine h3 receptor antagonists: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as... Agent: Evotec Ag

20120040953 - Compounds for the treatment of metabolic disorders: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.... Agent: Prosidion Limited

20120040955 - Fluoro substituted pyrimidine compounds as jak3 inhibitors: wherein AA, R2 to R7 and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as selective inhibitors of JAK3 over JAK2 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to... Agent:

20120040951 - Heteroaryl compounds useful as raf kinase inhibitors: The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.... Agent:

20120040950 - Isoindolinone inhibitors of phosphatidylinositol 3-kinase: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120040954 - Novel anti-inflammatory agents: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory... Agent:

20120040956 - Inhibitors of hif-1 protein accumulation: The invention relates to cyclopentabenzofuran derivatives for the treatment and/or prophylaxis of angiogenesis-related disorders.... Agent: Intermed Discovery Gmbh

20120040948 - Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy: e

20120040960 - 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2: wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting... Agent:

20120040959 - 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents: Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents.... Agent: Achillion Pharmaceuticals, Inc.

20120040958 - Indole carboxamides as ikk2 inhibitors: The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a... Agent: Glaxosmithkline LLC

20120040957 - Novel bicyclic antibiotics: Compounds of formula (I) wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl),... Agent: Basilea Pharmaceutica Ag

20120040962 - Fused ring inhibitors of hepatitis c: Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.... Agent: Presidio Pharmaceuticals, Inc.

20120040961 - Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, AbI, DCAMKL1, ABL1, AbI mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS 1, RPS6KA6, TAOK1, TAOK3,... Agent: Dana-farber Cancer Institute

20120040963 - 4-biphenyl-substituted pyrazolidin-3,5-dione derivatives: e

20120040964 - N-substituted piperidines and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Incyte Corporation

20120040966 - Anti-viral compounds, treatment, and assay: The compounds provided herein are suitable for inhibiting a virus in a patient and for treating a patient suffering from a viral infection such as an influenza virus. Also provided is a method for screening of compounds for use in treating and preventing viral infections. The assay screens compounds for... Agent: Southern Research Institute Office Of Commercialization And Intellectual Prop

20120040965 - Substituted azepino[4,3-b]indoles, pharmacological composition and a method for the production and use thereof: wherein: solid line together with the dotted line () represents a single or double bond; R1 and R2 independently of each other are amino group substituents selected from hydrogen; optionally substituted C1-C8 alkyl with substituents selected from optionally substituted aryl or 5-6-membered azaheterocyclyl; C1-C8 alkoxycarbonyl; optionally substituted phenyl; optionally substituted... Agent:

20120040968 - Diamino heterocyclic carboxamide compound: As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the... Agent: Waters Technologies Corporation

20120040967 - Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising... Agent: Cancer Research Technology Limited

20120040969 - N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor: The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.... Agent: Abbott Gmbh & Co. Kg

20120040971 - Benzodiazepinone compounds useful in the treatment of skin conditions: The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.... Agent: The Regents Of The University Of Michigan

20120040970 - Intranasal delivery system for dantrolene: The present invention provides a method for rapidly and reliably delivering dantrolene, or derivatives thereof, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment or prevention of malignant hyperthermia (MH), spasticity, and... Agent:

20120040972 - Dual modulators of 5ht2a and d3 receptors: wherein R1, R2, X and n are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence,... Agent:

20120040973 - Derivatives of [1,3]oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders: This invention relates to novel compounds of an 11 β-HSD1 inhibitor disclosed herein, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11/3-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel... Agent: Vitae Pharmaceuticals, Inc.

20120040975 - Bridged bicyclic heterocycle derivatives and methods of use thereof: The present invention relates to Bridged Bicyclic Heterocycle Derivatives, compositions comprising a Bridged Bicyclic Heterocycle Derivative, and methods of using the Bridged Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.... Agent:

20120040974 - Mif modulators: The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.... Agent: Yale University

20120040976 - Small molecule immunomodulators for alzheimer's disease: Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, ALS, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the... Agent: Human Biomolecular Research Institute

20120040977 - Inhibitors of hcv ns5a: Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.... Agent: Presidio Pharmaceuticals, Inc.

20120040978 - Heterocyclic fused cinnoline m1 receptor positive allosteric modulators: The present invention is directed to heterocyclic fused cinnoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to... Agent: Merck Sharp & Dohme Corp.

20120040979 - Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions: e

20120040980 - Quinazolinone compounds: The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I).... Agent: Prana Biotechnology Limited

20120040981 - Thienopyrimidine as cdc7 kinase inhibitors: e

20120040982 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions:

20120040983 - Phthalazine compounds as p38 map kinase modulators and methods of use thereof: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical... Agent: Amgen Inc.

20120040984 - Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof: The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.... Agent: Sanofi

20120040985 - Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity: wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5... Agent: Exelixis Patent Company LLC

20120040986 - Omega carboxyaryl substituted diphenyl ureas as raf kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent:

20120040987 - Derivatives of 6-(6-nh-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors: The invention relates to novel products of the formula (I) where: (II) is a single or double bond; Rb is a hydrogen or fluorine atom; Ra is a NH-Rc radical in which Rc is an optionally substituted heterocycloalkyl, aryl, heteroaryl or -alkylcycloalkyl radical; X is S, SO, or SO2; A... Agent: Sanofi

20120040989 - 2-hydroxyethyl-1h-quinolin-2-one derivatives and their azaisosteric analogues with antibacterial activity: e

20120040988 - Derivatives of 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione:

20120040990 - Indol-3-y-carbonyl-piperidin and piperazin-derivatives: wherein the residues R1 to R3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome,... Agent:

20120040991 - 3-azabicyclo [4.1.0] heptanes used as orexin antagonists: Disclosed are 3-azabicyclo[4.1.0]heptane derivatives of formula (I) and their use as orexin receptor antagonists.... Agent: Glaxo Group Limited

20120040993 - Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them: Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with... Agent: Yeda Research And Development Co., Ltd.

20120040992 - Oligooxopiperazines and methods of making and using them: The present invention relates to oligooxopiperazines and their use. Methods for preparing oligooxopiperazines are also disclosed.... Agent: New York University

20120040994 - Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin: A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs including (i) a Rho kinase inhibitor selected from the group consisting of (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and 1-(5-isoquinolinesulfonyl)-homopiperazine, or a salt thereof and (ii) a prostaglandin which is latanoprost or a salt of... Agent: Santen Pharmaceutical Co., Ltd.

20120040995 - Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are... Agent: The Board Of Trustees Of The University Of Illinois

20120040996 - 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position, preparation thereof, and therapeutic use thereof: The invention relates to 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position and of the formula (I) where R1, R2, R3, R4, R5 and n are such as defined in claim 1, to a method for preparing same, and to the therapeutic use of said compounds.... Agent: Sanofi

20120040998 - 2-alkyl piperidine mglur5 receptor modulators: The present invention is directed to 2-alkylpiperidines which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is... Agent:

20120040999 - P38 kinase inhibiting agents: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: Formula (I); are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis... Agent:

20120040997 - Vinyl-aryl derivatives for inflammation and immune-related uses: The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent:

20120041001 - Carbonylamino-derivatives as novel inhibitors of histone deacetylase: e

20120041000 - Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy: The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Astex Therapeutics Limited

20120041002 - Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists: wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment... Agent:

20120041003 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme: e

20120041004 - Fused pyrimidine-dione derivatives as trpai modulators: The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also... Agent:

20120041005 - Use of alkanoyl l-carnitine for the treatment of erectile dysfunction: Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin El, pentolamine and papaverine.... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a

20120041006 - Compositions for raising uric acid levels and methods of using the same: Compositions for the treatment of uric acid deficiency are disclosed. The compositions generally comprise either a precursor or derivative of uric acid, which, when administered to a patient, will result in a raising of the uric acid levels in that patient. The compositions can optionally comprise one or more additional... Agent:

20120041007 - Cdk inhibitor salts: The present invention relates to novel crystalline form(s) of water-soluble salts and of free base of a cdk inhibitor. Such crystal salts are for example fumarate, L-malate, maleate, succinate, adipate, malonate, glycolate, phosphate, mesylate, L-lactate, hydrochloride, di-hydrochloride, tri-hydrochloride. Hydrates and polymorphs of such new salt forms, a process for their... Agent: Nerviano Medical Sciences S.r.l.

20120041008 - 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use: Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders:... Agent:

20120041009 - Pyrimidine compound and its use in pest control: A pyrimidine compound represented by below formula (I) has excellent control activity against pests and is useful as an active ingredient of a pest controlling agent.... Agent: Sumitomo Chemical Company, Limited

20120041010 - Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan: The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such... Agent:

20120041011 - Substituted benzofused derivatives and their use as vanilloid receptor ligands: The present invention relates to substituted benzofused derivatives, which can he used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.... Agent: Glenmark Pharmaceuticals S.a.

20120041012 - Substituted spirocyclic amines useful as antidiabetic compounds: Substituted spirocyclic amines of structural formula I are selective antagonists of the somatostatin sub-type receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.... Agent:

20120041013 - New azacyclic compounds: b

20120041014 - Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents, a... Agent:

20120041016 - 11-aza, 11-thia and 11-oxa sterol compounds and compositions: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds... Agent:

20120041015 - Method and composition for treating nodulocystic and conglobate acne vulgaris: Methods and compositions are described for the treatment of very severe acne vulgaris, including nodulocystic acne and conglobate acne. Compounds which inhibit either or both type 1 and type 2 isoforms of steroid 5α-reductase are administered daily in either oral or topical formulations to patients suffering from severe forms of... Agent: Elorac, Ltd.

20120041017 - Pyridocarbazole type compounds and applications thereof: t

20120041018 - Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor: Octahydrobenzoisoquinoline modulators of dopamine receptors are described herein. Methods for using octahydrobenzoisoquinoline modulators of dopamine receptors in the treatment of dopamine dysfunction are also described herein.... Agent: Purdue Research Foundation

20120041019 - Protease inhibitors: Compounds useful as protease inhibitors are provided, as are methods of use and preparation of such compounds and compositions containing such compounds. In one embodiment, the compounds are useful for inhibiting HIV protease enzymes, and are therefore useful in slowing the proliferation of HIV.... Agent:

20120041020 - Methods of treatment utilizing semi-solid pharmaceutical compositions: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.... Agent: A.p. Pharma, Inc.

20120041021 - Process for preparing a semi-solid delivery vehicle and pharmaceutical compositions: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.... Agent: A.p. Pharma, Inc.

20120041022 - Process for preparing enantiomerically enriched alkaloids: s

20120041023 - Small molecule activators of mitochondrial function: Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula (I) are described that are beneficial in treating, for example, diseases and conditions such as Friedreich's ataxia, normal aging, and various neurodegenerative diseases... Agent:

20120041024 - Quinolyl amines as kinase inhibitors: t

20120041025 - Dihydrolipoic acid derivatives comprising nitric oxide and therapeutic uses thereof: Compounds are provided that comprise dinitroso-derivatives of dihydrolipoic acid. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating various diseases and disorders, including angina, hypertension, diabetes, dyslipidemia, renal insufficiency, myocardial infarction, stroke, atherosclerosis, and the target organ damage that accompanies these various diseases and disorders, are... Agent:

20120041026 - (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors: (R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol and its use in treating neurodegenerative disorders, is described herein.... Agent: Pfizer Inc.

20120041027 - Benzimidazoles which have activity at m1 receptor and their uses in medicine: )

20120041028 - Benzimidazoles which have activity at m1 receptor and their uses in medicine:

20120041029 - Compositions for drug delivery: Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent.... Agent: Dr. Reddy's Laboratories Limited

20120041030 - Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action: Disclosed are a novel pyridine thio derivative, and a pharmaceutical composition using the novel pyridine thio derivative, particularly a pharmaceutical composition having selective antibacterial activity against Helicobacter pylori. Specifically disclosed is a pyridine thio derivative represented by general formula (I) (wherein R1 and R2 each represents a hydrogen atom, a... Agent:

20120041031 - Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.... Agent: Allergan, Inc

20120041032 - Metalloprotein inhibitors: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3,... Agent: The Regents Of The University Of California, San Diego

20120041033 - Hydroxybenzoate salts of metanicotine compounds: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds,... Agent:

20120041034 - Sustained release aminopyridine composition: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Acorda Therapeutics, Inc.

20120041035 - Levamlodipine compound pharmaceutical composition: A levamlodipine compound pharmaceutical composition is provided, which contains levamlodipine or a pharmaceutically acceptable salt thereof, and chlorthalidone. In the present invention, levamlodipine and chlorthalidone are administrated in combination for treating hypertension, a high synergistic antihypertensive effect is achieved, and the edema side effect due to sodium and water retention... Agent: Shihuida Pharmaceuticals Group (jilin) Ltd

20120041038 - Amine derivative compounds for treating ophthalmic diseases and disorders: Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.... Agent: Acucela Inc.

20120041039 - Amine derivative compounds for treating ophthalmic diseases and disorders: Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.... Agent: Acucela Inc.

20120041037 - Composition that comprises at least one oxime and its use in therapeutics: A medication, a pharmaceutical composition, and method for the treatment of respiratory poisoning in animals and humans caused by organophosphorus compounds, whereby said medication and said pharmaceutical composition comprise at least one oxime and one blocker of organic cation transporters (OCT).... Agent: Serb

20120041036 - Substituted acylguanidine derivatives (as amended): It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT5A receptor modulating action and excellent pharmacological actions based on the action. The present... Agent:

20120041040 - Functionalized 4- and 5-vinyl substituted regioisomers of 1, 2, 3-triazoles via 1, 3-dipolar cycloaddition and polymers thereof: The present invention provides novel functionalized mixtures 4- and 5-vinyl substituted regioisomers of 1,2,3-triazoles via 1,3-dipolar cycloaddition. Functionalized alkyne moieties with a terminal alcoholic functionality are reacted with functionalized organic moieties with a terminal leaving group and an azide to provide an alcoholic functionalized mixture of 4- and 5-substituted regioisomers... Agent: Isp Investments Inc.

20120041041 - 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity: Compounds of formula (I) in free or salt or solvate form, wherein T has the meaning as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are... Agent: Novartis Ag

20120041042 - Scent ectoparasiticidal formulation: The present invention provides an improved-scent composition comprising metaflumizone, as well as a method for protecting against ectoparasite infestations in a warm-blooded animal.... Agent: Wyeth LLC

20120041043 - Sulfonamide compounds for the treatment of respiratory disorders: Compounds of formula (I) are agonists of PPARγ, useful for the treatment of respiratory disease; formula (I): wherein R1, R2 or R3 each independently represents halo, cyano, nitro, amino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxylic acid or an ester or amide thereof; R4 represents hydrogen or alkyl; m, n or p... Agent: Dr. Reddy's Laboratories Ltd

20120041044 - Process for the preparation of carvedilol and its enantiomers: The present invention relates to a process for the preparation of carvedilol as well as of the optically active R and S enantiomers thereof and of mixtures of these enantiomers and, more particularly, relates to an improved process for the preparation of carvedilol and its enantiomers characterized by the use... Agent: Zach System S.p.a.

20120041045 - Use of pharmaceutical compositions containing mesembrenone: The use of mesembrenone and medicaments and dietary supplements containing mesembrenone. The applicant has surprisingly found that mesembrenone exhibits potent PDE-4 inhibition properties and, in addition to being useful in treating conditions that respond to treatment with a PDE-4 inhibitor, has dual activity on account of its serotonin-uptake inhibition properties.... Agent: H.l. Hall & Sons Limited

20120041046 - Non-steroidal compounds for androgen receptor modulation: The present invention concerns compounds of general Formula (I): method of preparation and uses thereof.... Agent: Cnr - Consiglio Nazionale Delle Ricerche

20120041058 - Composition of traditional chinese medicine for reducing blood fat and preparation method thereof: Composition of traditional Chinese medicine for reducing blood lipid with components of the crude drug of artemisinins and the crude drug of ursolic acid, wherein the ratio of the crude drug of artesunate and the crude drug of ursolic acid is 1:25-25:1 by weight. The preparation method of such composition... Agent: Anji Green Life Biotech Co., Ltd.

20120041059 - Bioactive compositions from theacea plants and processes for their production and use: The present invention relates to isolated bioactive compositions containing bioactive fractions derived from Theacea plants. The present invention also relates to bioactive topical formulations containing the bioactive compositions. The present invention further relates to methods of using the bioactive compositions of the present invention, including, for example, methods for inhibiting... Agent: Akzo Nobel Surface Chemistry LLC

20120041060 - Treatment for altitudinal hypoxia: The invention provides a method for treating hypoxia caused by high altitude by administering to a subject a compound that reduces the P50 of hemoglobin for oxygen.... Agent: Aesrx LLC

20120041061 - Use of prodrugs of gaba analogs for treating diseases: Methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel syndrome, social phobia, Parkinson's disease, asthma, cough, or chronic obstructive pulmonary disease, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel... Agent: Xenoport Inc.

20120041062 - Compound of salvianolic acid l, preparation method and use thereof: The present invention relates to a new compound of salvianolic acid L, its preparation method, a pharmaceutical composition containing the salvianolic acid L, and its use for preparing a medicament for treating cardio-cerebrovascular diseases.... Agent: Tianjin Tasly Pharmaceutical Co., Ltd.

20120041063 - Antitumoral compounds: e

20120041064 - Skin treatment: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.... Agent: Peplin Research Pty Ltd

20120041065 - Lauric acid distillate for animal feed: Provided are novel methods and formulations for enhancing feed efficiency and reducing mortality in food animals.... Agent: Eli Lilly And Company

20120041066 - Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways: Describe herein are medical foods, pharmaceutical compositions, methods of compounding them, and method of using them for the treatment of developmentally-based neuropsychiatric disorders including particularly autism, ADHD, and persistent developmental disorders. The medical foods and pharmaceutical compositions typically include a methylglycine compound or precursor compound and an acetylcysteine compound or... Agent:

20120041067 - Methods of inducing terminal differentiation: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high.... Agent:

20120041068 - Extended release pharmaceutical preparations for active pharmaceutical ingredients with ph dependent solubility: An extended release preparation of an active pharmaceutical ingredient with pH dependent solubility dissolved or dispersed in a semi-solid or liquid nonionic solubilizer and further containing a non-pH dependent sustained release agent as well as a process for the preparation thereof are provided.... Agent: Aptapharma, Inc.

20120041070 - Methods of treating cancer having an aberrant egfr or kras genotype: The invention relates to the treating cancer having an aberrant EGFR or KRAS genotype, with an AMPK activator, as well as related methods, compounds and compositions.... Agent:

20120041069 - Sglt2 inhibitor dosage forms: A pharmaceutical composition comprising a sodium-dependent glucose transporter (SGLT2) inhibitor and a biguanide, wherein at least one of the active agents is in slow release form, is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a sodium-dependent glucose transporter (SGLT2)... Agent: Nectid Inc.

20120041071 - Tapentadol for treating pain due to osteoarthritis: The use of tapentadol for treating pain due to osteoarthritis.... Agent: Gruenenthal Gmbh

20120041072 - Antiviral agent: A compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to... Agent: Nippon Soda Co., Ltd.

20120041073 - Stabilized mutant opsin proteins: Methods and compositions for stabilizing opsin protein in a vertebrate visual system are provided by administration of opsin-binding synthetic retinoids.... Agent: University Of Washington

20120041074 - Method of inducing neovascularization: A method for inducing neovascularization in which a pharmaceutically effective amount of polyethylene glycol (PEG) is injected into the tissue of the subject for purposes of accelerating wound healing and mimicking age related macular degeneration, cancer, tumors, and atherosclerosis for further research purposes.... Agent:

20120041075 - Ethanol compositions: In one embodiment, the present invention is to an ethanol composition comprising at least 85 wt. % ethanol and from 95 wppm to 850 wppm isopropanol.... Agent: Celanese International Corporation

20120041076 - Gel forming solution and method for producing gel: A method for producing a gel includes a liquid droplet ejection step in which a first liquid is ejected in the form of a droplet to a second liquid to allow the first liquid and the second liquid to react with each other, thereby producing a gel. The first liquid... Agent: Seiko Epson Corporation

20120041077 - Organoleptic compounds and their use in perfume compositions: m

20120041079 - Dextran functionalized by hydrophobic amino acids:

20120041078 - Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer: The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.... Agent: Senomyx, Inc.

20120041080 - Cellulose solutions comprising tetraalkylammonium alkylphosphate and products produced therefrom: This invention relates a cellulose solution comprising cellulose and at least one tetraalkylammonium alkylphosphate and processes to produce the cellulose solution. Another aspect of this invention relates to shaped articles prepared from a cellulose solution comprising cellulose and at least one tetraalkylammonium alkylphosphate. Another embodiment of this invention relates to... Agent: Eastman Chemical Company

20120041081 - Biogenic silica from silica-containing plant material such as rice hulls: A biogenic silica from a plant material such as rice hulls, rice straw and so forth containing a significant amount of silica for use as an anti-caking agent, excipient or flavor carrier. When the plant material is certified as organic, the silica may also be certified as organic. The plant... Agent:

20120041082 - Methods of using smad3 and jak2 genetic variants to diagnose and predict inflammatory bowel disease: Disclosed are methods of diagnosing Inflammatory Bowel Disease by determining the presence or absence of genetic variants at SMAD3 and/or JAK2 loci. Provided is a method of diagnosing a Crohn's Disease subtype in an individual by determining the presence or absence of a risk variant at the SMAD3 and/or JAK2... Agent: Cedars-sinai Medical Center

  
02/09/2012 > 187 patent applications in 142 patent subcategories. patent applications/inventions, industry category

20120035093 - Amphiphilic polymer-protein conjugates and methods of use thereof: Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided.... Agent:

20120035096 - Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function: There is provided an agent having at least one of an improving effect on vascular endothelial functions and an inhibitory effect on vascular intimal thickening, as well as a prophylactic of arteriosclerosis, which have excellent safety, improve functions associated with the vascular endothelium, have effects of preventing various diseases associated... Agent: Calpis Co., Ltd.

20120035094 - F11 receptor (f11r) antagonists as therapeutic agents: The present invention provides a compound including a peptidomimetic which interacts sterically with the binding site of a F11R molecule, the peptidomimetic including a peptidomimetic having the SEQ ID NO: 4D. The present invention also provides a method for treating a disorder comprising administering peptide 4D to a mammal.... Agent:

20120035095 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: The Regents Of The University Of California

20120035097 - Methods of treating bacterial infections using oritavancin: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction... Agent: Targanta Therapeutics Corp.

20120035098 - Novel antiviral agent: e

20120035099 - Fgf21 analogues and derivatives: Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.... Agent: Novo Nordisk A/s

20120035100 - Satiation peptide administration: Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide... Agent:

20120035101 - Long-acting growth hormone and methods of producing same: Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing... Agent:

20120035102 - Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.... Agent: Albany Molecular Research, Inc.

20120035104 - Insulin derivatives: The present invention relates to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which... Agent: Novo Nordisk A/s

20120035103 - Method for administration of insulin and pharmaceutical composition thereof: The present invention provides pharmaceutical compositions including alkylglycosides admixed with at least one of fast-acting and long-acting insulin analogs for treatment of disorders, such as diabetes.... Agent:

20120035105 - Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments: The present invention includes a pharmaceutical composition comprising HDV insulin or oral HDV insulin, and one or more additional therapeutic agents useful for the treatment of diabetes and diabetes related ailments. The present invention also includes a method of making the pharmaceutical inventions of the application. The present invention further... Agent: Sdg, Inc.

20120035106 - Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes: The present invention is related with the field of the medicine, particularly with the use of an APL peptide or its analogues derived from the human heat shock protein of 60 kDa, for the manufacture of a pharmaceutical composition for the treatment of Crohn's disease, ulcerative colitis and diabetes mellitus... Agent:

20120035107 - Compositions for achieving a therapeutic effect in an anatomical structure: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.... Agent:

20120035108 - Spray base material including low-molecular gelator: There is provided a spray base material that can be safely used with a sense of security, that prevents leakage of liquid from a spray container, that is sprayable under any condition (when inverted, for example), that is sprayable to achieve uniform coating of the surface of an object (surface... Agent: Nissan Chemical Industries, Ltd.

20120035109 - Follicle stimulating hormone superagonists: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared... Agent: Trophogen, Inc.

20120035110 - Method of producing recombinant high molecular weight vwf in cell culture: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with... Agent: Baxter International Inc.

20120035111 - Therapeutic application of adiponectin in patients with acute myocardial infarction: A therapeutic method for cardiac diseases such as angina, myocardial infarction, arrhythmia (ventricular tachycardia, ventricular fibrillation and atrial fibrillation) is provided. The method is characterized by intracoronary administration of adiponection to mammals.... Agent: National University Corporation Nagoya University

20120035112 - Neuronal differentiation-inducing peptide and use thereof: A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.... Agent: Toagosei Co., Ltd.

20120035113 - Methods of reducing trail-induced apoptosis by trail isoforms: This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided.... Agent:

20120035114 - Inhibitors of stat3 and uses thereof: Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such... Agent: Board Of Regents, The University Of Texas System

20120035115 - Chemical modifications of monomers and oligonucleotides with cycloaddition: m

20120035116 - Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut: This invention relates to methods of preserving the integrity of peptides in the gut. In particular it concerns the use of certain compounds as inhibitors of gut proteases. Compounds identified as having gut protease inhibitory activity are biguanides, certain bile acids and pharmaceutically acceptable salts of these compounds. This activity... Agent:

20120035117 - Process for synthesis of cyclic octapeptide: This invention relates a process for preparing octreotide and derivatives thereof. The starting material, Cys(Trt)-2-Chlorotrityl resin is coupled with various amino acids to obtain a protected heptapeptide of formula (2): Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-2-Chlorotrityl resin. The linear protected peptide of formula (2) is cleaved from the support using TFA5TIS and water to yield... Agent:

20120035119 - Extracts and compounds from ficus benghalensis for increasing hair growth and decreasing hair loss: This application discloses natural product extracts and compounds from an aerial root of a Ficus plant, such as Ficus benghalensis. The application also discloses the use of natural product extracts and compounds from Ficus plants for increasing hair growth and decreasing hair loss. Synthetic formulations comprising various compounds identified in... Agent: Alvia Fze

20120035120 - Glycolipids as treatment for disease: This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.... Agent: Seneb Biosciences, Inc.

20120035118 - Pharmaceutical combinations: Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia,... Agent: Altherx, Inc.

20120035121 - Antibiotic product, use and formulation thereof: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more... Agent: Shionogi Inc.

20120035123 - Combination of compounds for treating or preventing skin diseases: A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a... Agent: Galderma Research & Development

20120035122 - Isoxazoline derivatives as antiparasitic agents: c

20120035125 - Fulvic acid in combination with fluconazole or amphotericin b for the treatment of fungal infections: A combination of fulvic acid or a salt, ester, or derivative thereof and an antifungal compound selected from fluconazole and amphotericin B for use in the treatment or prophylaxis of a disease or condition of the human or animal body is described. The fulvic acid can be CHD-FA.... Agent: Natracine Uk Limited

20120035124 - Use of nifuratel to treat infections caused by atopobium species: The present invention is directed to the use of nifuratel, or a physiologically acceptable salt thereof, to treat' infections caused by Atopobium species. The invention is further directed to the use of nifuratel to treat bacteriuria, urinary tract infections, infections of external genitalia in both sexes, as well as bacterial... Agent: Polichem Sa

20120035126 - Compounds for reducing drug resistance and uses thereof: This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds.... Agent:

20120035240 - Conserved hbv and hcv sequences useful for gene silencing: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV... Agent: Alnylam Pharmaceuticals, Inc.

20120035243 - Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders: The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for administering inhibitors of the two miRNAs that achieve efficient,... Agent: Board Of Regents, The University Of Texas System

20120035245 - Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the stabilization of mast cells, in particular that inhibit mast cell degranulation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by mast... Agent:

20120035244 - Parp1 targeted therapy: The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to PARP1 proteins and nucleic acids as clinical and research targets for cancer.... Agent: The Regents Of The University Of Michigan

20120035242 - Pharmaceutical composition for treating obesity or diabetes: The invention is intended to provide a pharmaceutical composition for treating or preventing obesity or type II diabetes and a method for treatment for them. A pharmaceutical composition comprising an Acsl-1 inhibitor of this invention as an active ingredient is useful for prevention or treatment of obesity or type II... Agent: Shionogi & Co., Ltd.

20120035247 - Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of STAT6 gene expression and/or activity, and/or modulate a STAT6 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp.

20120035246 - Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton: Provided is a novel nucleic acid molecule that can be produced easily and efficiently and can inhibit the expression of a gene. The nucleic acid molecule is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes:... Agent: Bonac Corporation

20120035241 - Use of inhibitors of plac8 activity for the modulation of adipogenesis: The present invention concerns Plac8, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Plac8 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Plac8 activity as well screening test for identification... Agent: Sanofi-aventis

20120035248 - Method for inhibiting the activity of mir-155: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Regulus Therapeutics, LLC.

20120035249 - Targeted mucosal treatment of obesity and diabetes: A technique for treating obesity, diabetes, and other endocrinological disorders by removal of the omentum by endoscopic and oral approaches is described herein. The removal of the omentum interferes with the glucose absorption or ghrelin production thereby improving and correcting the obesity and diabetes.... Agent:

20120035128 - Polysaccharide derivative and hydrogel thereof: Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C1-10 hydrocarbon group, Y is a polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R2,... Agent: Teijin Limited

20120035127 - Process for the production of a composition, the composition and the use thereof as food additive: The present invention relates to a process for the production of a functional food additive, such as a prebiotic composition, comprising the steps of. (a) providing a plant based material wherein the plant is selected from the group consisting of cereals, legumes, tubers and mixtures thereof, wherein said plant based... Agent: Universite De Liege Gembloux Agro-bio Tech

20120035129 - Hydrogel tissue adhesive having reduced degradation time: A hydrogel tissue adhesive having decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm polyether amine in the presence of an oligomer additive, which promotes the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive... Agent: Actamax Surgical Materials LLC

20120035130 - Chirally correct retinal cyclodextrin acetals for clarifying skin complexion: The present invention discloses certain chirally correct polyene cyclodextrin acetals and hemiacetals (formula I) that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and... Agent: Island Kinetics Inc.

20120035131 - Pyrazoline compounds: e

20120035132 - Boron-containing small molecules: Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.... Agent: Anacor Pharmaceuticals, Inc.

20120035133 - Lyophilization cakes of proteasome inhibitors: Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use.... Agent: Cephalon, Inc.

20120035134 - Chemical compounds: o

20120035135 - Treatment of transgenic crops with mixtures of fiproles and chloronicotinyls: The Invention relates to methods for increasing the production potential of plants and/or controlling pests in plants with at least one transgenic modification related to yield increase as compared to a corresponding wild-type plant, comprising treating the location where the plant with at least one transgenic modification is growing or... Agent: Bayer Cropscience Ag

20120035136 - Antisense antiviral compounds and methods for treating a filovirus infection: The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola... Agent: Avi Biopharma, Inc.

20120035137 - Use of inositol-tripyrophosphate in treating tumors and diseases: Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce... Agent:

20120035138 - Bisphosphonate formulation: A bisphosphonate is formulated with an agent to reduce surface tension and/or reduce foaming in the stomach, leading to reduced reflux and oesophageal irritation in use and increased patient compliance.... Agent: Selamine Limited

20120035139 - Gamma-amino-butyric acid derivatives as gabab receptor ligands: Gamma-amino-butyric acid derivatives that are GABAB receptor ligands, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives and pharmaceutical compositions thereof for treating diseases are disclosed.... Agent: Xenoport, Inc.

20120035140 - Carbamoylphosphonates as inhibitors and uses thereof: The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.

20120035141 - Cycloalkyl-hydroxyl compounds and compositions for cholesterol management: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Esperion Therapeutics, Inc.

20120035142 - Polymorphs of darunavir: The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection.... Agent: Mapi Pharma Limited

20120035143 - Drug combinations containing pde4 inhibitors and nsaids: e

20120035144 - Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it.: a) a biopolymer in the form of Chitosan, b) active Pharmaceutical Ingredients (APIs), in the form of fusidic acid that has been generated in situ from sodium fusidate Hydrocortisone acetate & clotrimazole, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants,... Agent: Apex Laboratories Private Limited

20120035145 - Methods of treating multiple myeloma using melphalan, prednisone and lenalidomide: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent:

20120035146 - Implants and methods for treating inflammation-mediated conditions of the eye: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration... Agent: Allergan, Inc.

20120035147 - Method for treatment of diseases: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering... Agent: Dmi Acquisition Corp.

20120035148 - Ophthalmic compositions and methods for treating ophthalmic conditions: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component.... Agent: Allergan, Inc

20120035152 - Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors: The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, q, A, B, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Astex Therapeutics Limited

20120035153 - Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors: The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Astex Therapeutics Limited

20120035150 - Mif inhibitors and their uses: The invention relates to MIF inhibitors; compositions comprising an effective amount of a MIF inhibitor; and methods for treating or preventing diseases associated with MIF.... Agent:

20120035149 - Prokineticin receptor antagonists and uses thereof: Contemplated compounds, compositions, and methods of prokineticin antagonists are presented where a prokineticin antagonist is used in the treatment and prevention of various conditions and disorders, and especially type II diabetes.... Agent: The Regents Of The University Of California

20120035151 - Substituted dihydropyrazolones and their use: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.... Agent: Bayer Harma Aktiengesellschaft

20120035155 - Indole-2-carboxamide deivative: To provide an indole compound having a human QRFP receptor antagonistic activity and useful as a preventive or a remedy for various disorders. A compound of a formula (I) or a pharmaceutically-acceptable salt thereof is provided: [wherein, R1 represents a hydrogen atom, a halogen, a C1-6 alkyl, etc,; R2 represents... Agent: Msd K.k.

20120035154 - Modulators of cellular adhesion: and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular... Agent: Sarcode Bioscience, Inc.

20120035156 - Combination of glyt1 compound with antipsychotics: The present invention relates to a pharmaceutical combination of a glycine transporter inhibitor (GlyT1) and an atypical antipsychotic drug which may be used for the treatment of positive and negative symptoms of schizophrenia.... Agent:

20120035157 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use: e

20120035158 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions:

20120035159 - Substituted isoquinoline derivative: The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein X and Y each independently represent a direct bond, NH, CH═CH,... Agent: D. Western Therapeutics Institute, Inc

20120035160 - New family of antichagasics derived from imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxide: Compounds derived from imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides, for use as a drug or pharmaceutical composition for treatment of parasitic diseases, preferably of diseases caused by parasites of the Trypanosoma genus, and more preferably for treatment of the Chagas disease. Furthermore, the invention also relates to the pharmaceutical compositions comprising said compounds.... Agent: Consejp Superior De Investigaciones Cientificas (cisic)

20120035161 - Novel compositions and methods of treating diseases using the same: The invention includes compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, treating diseases associated with activated lymphocytes, or treating PAH.... Agent: Corridor Pharmaceuticals, Inc.

20120035162 - Process for preparation of high-purity meloxicam and meloxicam potassium salt: The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid... Agent:

20120035164 - Chemical compounds: The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound... Agent:

20120035163 - Novel fused ring compound and use thereof: e

20120035165 - Use of fungicidal compound compositions for controlling certain rust fungi: The present invention relates to the use of a fungicidal composition comprising at least one carboxamide and at least one further compound selected from strobilurins or from triazoles, for controlling certain rust fungi, such as soy bean rust and coffee rust, in crop protection.... Agent: Bayer Cropscience Ag

20120035166 - Methods of treating a pulmonary bacterial infection using fluoroquinolones: Disclosed herein are methods of treating a pulmonary bacterial infection comprising bacteria growing under anaerobic conditions using a fluoroquinolone antibiotic. The fluoroquinolone antibiotic may, for example, be levofloxacin or ofloxacin. Also disclosed are methods of inhibiting bacteria growing under anaerobic conditions by exposing the bacteria to an amount of fluoroquinolone... Agent:

20120035169 - Aerosol formulation for the inhalation of beta-agonists: s

20120035167 - Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors: The present invention relates to novel indole and benzoxazine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic... Agent:

20120035168 - N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides: e

20120035170 - Novel unsaturated tetracyclic tetrahydrofuran derivatives:

20120035171 - Bicyclic heterocyclyl derivatives as fgfr kinase inhibitors for therapeutic use: The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Astex Therapeutics Limited

20120035172 - Purinone derivatives as hm74a agonists: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.... Agent: Incyte Corporation

20120035173 - Di-substituted amides for enhancing glutamatergic synaptic responses: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related... Agent:

20120035174 - Salts of n-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide: Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide are prepared and characterized.... Agent: Novartis Ag

20120035176 - Analogs of 3-o-acetyl-11-keto-beta-boswellic acid: Analogs of 3-O-acetyl-11-keto-beta-boswellic acid and their method of preparation are presented. The analogs may be used as anti-inflammatory and anti-cancer agents. The compounds inhibit 5-lipoxygenase enzyme and various cell lines related to inflammation as well as to cancer showing a significantly better efficacy when compared to the normal boswellic acids.... Agent: Laila Nutraceuticals

20120035175 - Novel salts as anti-inflammatory, immunomodulatory and anti-proliferatory agents: a

20120035178 - Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.... Agent: Bristol-myers Squibb Company

20120035177 - Tablet formulation for p38 inhibitor and method: A tablet formulation is provided which includes a medicament which is a pharmaceutically acceptable salt of a p38 inhibitor, such as the p38 HCl salt of the structure Formula (I) and which has good physical stability when stored at up to 25 C./60% RH in closed containers with desiccant. The... Agent: Bristol-myers Squibb Company

20120035179 - Modulators of atp-binding cassette transporters: t

20120035181 - Antiparasitic agent for fish and method of controlling proliferation of fish parasites: A method of controlling proliferation of fish parasites comprising the administration of 1 to 50 mg/kg fish body weight/day of an inhibitor of folate synthesis and/or an inhibitor of folate activation to fish continuously for 1 to 2 weeks. Using a combination preparation composed of an inhibitor of folate synthesis... Agent: Nippon Suisan Kaisha, Ltd.

20120035182 - Methods of treatment of chronic pain using eszopiclone: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.... Agent: Sunovion Pharmaceuticals Inc.

20120035180 - Pharmaceutical composition for treating cancer comprising chlorin e6-folic acid conjugate compound and chitosan: The present invention relates to a pharmaceutical composition for the treatment of cancer comprising a chlorin e6-folic acid conjugate compound and chitosan, and more particularly, to a pharmaceutical composition for photodynamic therapy of solid tumors comprising the novel chlorin e6-folic acid conjugate compound or a pharmaceutically acceptable salt thereof and... Agent: Diatech Korea Co., Ltd.

20120035183 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one... Agent:

20120035184 - Methods for inducing tumor regression, inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyltransferase i inhibitors: Methods of inducing tumor regression, inhibiting tumor growth, and inducing apoptosis with selective peptidomimetic inhibitors of geranylgeranyltransferase I (GGTase I), are provided. In one aspect, GGTI-2418 and its methylester GGTI-2417, increase levels of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 and induce breast tumor regression in vivo. In another aspect, GGTI-2417... Agent: H. Lee Moffitt Cancer Center And Research Institute, Inc.

20120035185 - Method of using flibanserin for neuroprotection: The present invention relates to the use of 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, optionally in the form of its pharmaceutically acceptable acid addition salts and optionally in the form of its hydrates or solvates, for preparing a pharmaceutical composition with a neuroprotective activity.... Agent:

20120035186 - Composition comprising azole fungicide and water soluble metal salt: Hair treatment composition comprising an azole fungicide and zinc gluconate and wherein the composition does not comprise Trichogen®.... Agent:

20120035187 - Anti-neurodegenerative disease agent: wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of... Agent: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

20120035188 - Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.... Agent: H. Lundbeck A/s

20120035189 - Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.... Agent: Bristol-myers Squibb Company

20120035190 - E-type phenyl acrylic ester compounds containing substituted anilino pyrimidine group and uses thereof: Disclosed is a kind of E-type phenyl acrylic ester compound containing substituted anilino pyrimidine group, which is shown by general structure formula I, wherein each substituent is defined as that in the description. The compounds of general formula I show high insecticidal and acaricidal activities to adults and nymphs of... Agent:

20120035191 - Deuterium-enriched pyrimidine compounds and derivatives: for the prevention and treatment of cancer including brain cancer, breast cancer, blood cancer, colorectal cancer, lung cancer, liver cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer; tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia,... Agent:

20120035193 - 6-amino-purin-8-one compounds: wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various... Agent: Glaxosmithkline LLC

20120035192 - Selective antagonists of a2a adenosine receptors: e

20120035194 - Substituted 2-amino-fused heterocyclic compounds: or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such... Agent: Pfizer Inc.

20120035195 - 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds:

20120035196 - Carboxylic acid compound: The present inventors have extensively studied a compound having a GPR40 agonistic activity, and as a result, they have found that the compound (I) of the present invention or a pharmaceutically acceptable salt thereof, in which a carboxylic acid is bonded to a bicyclic or tricyclic moiety through methylene, and... Agent:

20120035198 - Antiviral compounds and methods of using thereof: Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral... Agent:

20120035197 - Novel use of fibrates: The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the manufacture of a drug for the treatment of sleep apnea, sleep apnea syndrome, in particular obstructive sleep apnea or obstructive... Agent: Fournier Laboratories Ireland Limited

20120035200 - Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering: The invention relates to compounds of the formula (I), where the symbols have the meaning given in the specification, for use in a method for treating cancer, to use of these compounds for the manufacture of a pharmaceutical composition for the treatment of cancer, and to methods of treatment for... Agent: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

20120035199 - Spiroheterocyclic compounds and their uses as therapeutic agents: k, j, p, Q, R1, R3a, R3b, R3e, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical... Agent: Xenon Pharmaceuticals Inc.

20120035201 - Spiroheterocyclic pyrrolidine dione derivatives used as pesticides: Compounds of the formula (I) wherein the substituents are as defined in claim 1 are useful as pesticides.... Agent: Syngenta Crop Protection LLC

20120035202 - Rifaximin compositions and method of use: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.... Agent: Alfa Wassermann, S.p.a.

20120035203 - Butaclamol for the treatment of amyotrophic lateral sclerosis: The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.... Agent: Cambria Pharmaceuticals, Inc.

20120035204 - Methods for treating obesity and disorders associated with hyperlipidemia in a mammal: The disclosure relates to methods for treating hyperlipidemia in a mammal. The present disclosure also relates to methods for treating and/or controlling obesity in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and a DGAT inhibitor (for example,... Agent:

20120035205 - Treatment for basal cell carcinoma: The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is... Agent: Graceway Pharmaceuticals. LLC

20120035206 - Preparation and application of novel antibacterial and anticancer compounds and their derivatives: Novel antibiotic and anticancer compounds of formula I, II, III, IV, derivatives, ostereoisomer, racemic and noracemic mixture of ostereoisomer, or the pharmaceutically acceptable salts or solvates of these compounds are disclosed. The preparation, pharmaceutical composition and biological activity of these compounds are disclosed.... Agent:

20120035207 - Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome: The invention provides a method of treating a condition selected from hearing disorders, vestibular disorders, attention disorders, intention tremor and restless leg syndrome comprising administering to a human patient in need thereof a therapeutically effective amount of a compound which is an agonist at GABAA receptors which comprise an α... Agent:

20120035209 - Hydroxy substituted 1h-imidazopyridines and methods: Hydroxy substituted 1H-imidazo[4,5-c]pyridin-4-amines, with a hydroxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Pfizer Inc.

20120035208 - Pyrazolopyridine pi3k inhibitor compounds and methods of use: Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula... Agent:

20120035210 - 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases: wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.... Agent:

20120035211 - Novel polymorphs of saquinavir: The present invention provides novel polymorphs of saquinavir, processes for their preparation and pharmaceutical compositions comprising them. The present invention also provides a process for purification of saquinavir. The present invention further provides a novel process for preparation of known saquinavir crystalline form I.... Agent: Hetero Research Foundation

20120035212 - (l)-malate salt of n-(4-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at... Agent: Exelixis, Inc.

20120035213 - Quinoline derivative: s

20120035214 - Renin inhibitors: The present invention relates to biaryl piperidine-based renin inhibitor compounds, and their use in treating cardiovascular events and renal insufficiency.... Agent: Merck Sharp & Dohme Corp.

20120035215 - Method of predicting a predisposition to qt prolongation: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound... Agent: Vanda Pharmaceuticals, Inc.

20120035216 - Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms via the oral transmucosal route of a subject for treatment of pain.... Agent:

20120035217 - Bis aromatic compounds for use as ltc4 synthase inhibitors: wherein Y, ring A, D1, D2a, D2b, D3, L1, Y1, L2 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a... Agent: Biolipox Ab

20120035219 - Compound for the treatment of tuberculosis: (5R)-3-[4-[1-[(2S)-2,3-dihydroxypropanoyl]-3,6-dihydro-2H-pyridin-4-yl]-3,5-difluoro-phenyl]-5-(isoxazol-3-yloxymethyl)oxazolidin-2-one, or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, for use in the treatment of Mycobacterium tuberculosis.... Agent: Astrazeneca Ab

20120035218 - Pest control composition: R

20120035220 - Method of fungal pathogen control in grass or turf: Disclosed is a method of controlling fungal organisms in turfgrass with imidacloprid and optionally one or more other fungicides.... Agent:

20120035221 - Method of fungal pathogen control in grass or turf: Disclosed is a method of controlling fungal organisms in turfgrass with imidacloprid and optionally one or more other fungicides.... Agent:

20120035222 - Solid forms of 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1h-imidazol-4-ylethynyl]-pyridine: The present invention relates to mono-sulfate and hemi-sulfate salts of 2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine, to crystalline and amorphous forms thereof and to their use in pharmaceutical formulations.... Agent:

20120035223 - Liquid pest control formulation: The present invention relates to a liquid pest control system that includes a synthetic pyrethroid as a pest control active ingredient and an agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof, to reduce or eliminate paresthesia of the... Agent: Redline Products, Inc.

20120035224 - Betulin derived compounds as anti-feedants for plant pests: The invention relates to compounds derived from betulin, and to the use thereof in plant pest control, particularly as antifeedants for butterfly larvae, beetles and snails. Further, the invention relates to novel betulin derivatives and methods for the production thereof either directly from betulin, or via intermediates derived therefrom.... Agent: Valtion Teknillinen Tutkimuskeskus

20120035225 - Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics: Methods for treating hyperlipidemia with intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, without causing drug-induced hepatotoxicity to a level which would require discontinuation of the therapy, whereby a majority of the nicotinic acid is release and metabolized in the individual within about 5 to about 9 hours. The... Agent:

20120035226 - Oxadiazole derivatives: The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.... Agent: Merck Serono Sa

20120035227 - Deuterium-enriched ixabepilone: The present application describes deuterium-enriched ixabepilone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20120035228 - Microbicidal compositions: The invention relates to synergistic mixtures of o-phenylphenol with other microbicidally active compounds, such as bronopol (2-bromo-2-nitro-1,3-propanedial), 2-methyl-2H-isothiazol-3-one, 1,2-dibromo-2,4-dicyanobutane.... Agent: Lanxess Deutschland Gmbh

20120035229 - Compositions containing 1,2-benzisothiazolin-3-one: e

20120035230 - Compounds, compositions, and methods for the treatment of beta-amyloid diseases and synucleinopathies: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent:

20120035231 - Specific diarylhydantoin and diarylthiohydantoin compounds: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may... Agent:

20120035232 - Use of angiotensin ii agonists: m

20120035233 - Medicinal cream made using miconazole nitrate and chitosan and a process to make the same: The present invention is directed to a composition for treating fungal skin infections, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antifungal active ingredient. It discloses a composition for treating fungal skin infections along with skin rejuvenation containing a)... Agent: Apex Laboratories Private Limited

20120035234 - Composition comprising free amino acids: A composition is described that can be used in prevention or treatment of patients having impaired gastro-intestinal tract function. The composition comprises free amino acids including about 9.0% to about 17.0% glutamic acid. Methods of treatment of impaired gastro-intestinal tract function are described.... Agent: Nestec S.a.

20120035235 - Methods of treating alpha adrenergic mediated conditions: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.... Agent: Allergan, Inc.

20120035237 - Pyrazole and triazole carboxamides as crac chann el inhibitors: The present invention relates to amide compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing these compounds and to their use in therapy.... Agent:

20120035236 - Pyrazolyl acrylonitrile compounds and uses thereof: e

20120035238 - Compounds and methods for treating cancer and viral infections: The present application relates to the use of one or more compounds of Formula (I) or pharmaceutically acceptable solvates or prodrugs thereof, for treating cancer or for treating or preventing a viral infection.... Agent: Goff Hill Limited

20120035239 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses: e

20120035250 - Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific... Agent: Phenomenome Discoveries Inc.

20120035251 - Thiophene inhibitors of ikk-b serine-threonine protein kinase: The invention provides a compound which is (a) a thiophene carboxamide derivative of formula (IA) or (IB), or a tautomer thereof; or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof, wherein L1, A1 and W are as defined herein. The compounds are useful as IKKβ inhibitors. The compounds... Agent: Chroma Therapeutics Ld.

20120035253 - Crystalline forms of genistein: The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline... Agent:

20120035254 - Inhibitor for elevation of gip level: Provided is a GIP-increase inhibitor, which is customary used for food production, is excellent in safety, and is useful for, for example, a medicine or a food. The GIP-increase inhibitor contains catechins as active ingredient.... Agent: Kao Corporation

20120035252 - Polyphenol-rich extract from plant material: A process is provided for preparing (1) a first composition obtained by extracting a plant material with a single phase mixture of water and at least a first organic solvent under agitation so as to obtain a first extract rich in polyphenol oligomers, wherein the first composition is the first... Agent:

20120035255 - Derivative of [(3-hydroxy-4 pyron-2-yl)-methyl]-amine and use thereof as anti-neoplastic drugs: The present invention relates to compounds having general formula (I), i.e. poly-alkyl-bis-maltolic molecules and in particular to derivates of [(3-hydroxy-4-pyron-2-yl)methyl]-amine and pharmaceutically acceptable salts thereof, and to the use thereof as anti-neoplastic drugs, in particular, for the preparation of a medicament for the treatment of neoplastic diseases.... Agent: Universita' Degli Studi Di Urbino

20120035256 - Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease: The subject application relates to methods of treatment of peripheral vascular disease (PVD) as well as ischemic osteonecrosis, peritoneal ischemia, chronic ocular disease, macular degeneration, or diabetic retinopathy, comprising administering a therapeutically effective amount of a trans carotenoid. The invention also relates to the use of such carotenoids as pretreatments... Agent: Diffusion Pharmaceuticals LLC

20120035257 - Histone deacetylase inhibitors: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of... Agent:

20120035258 - Methods of using prodrugs of pregabalin: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing... Agent: Xenoport, Inc.

20120035259 - Controlled release of nitric oxide and drugs from functionalized macromers and oligomers: The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as... Agent: Bezwada Biochemical, LLC

20120035260 - Tellurium-containing compounds for affecting female's reproductive system following chemotherapy and/or radiotherapy: Use of tellurium-containing compounds in a method of conception and/or for maintaining and/or augmenting fertility in female following chemotherapy and/or radiotherapy is disclosed. The tellurium-containing compound is utilized in combination with a chemotherapeutic agent and/or radiation, such that the female treated by the chemotherapeutic agent and/or radiation and by the... Agent: Biomas Ltd.

20120035261 - Deuterium-enriched saxagliptin: The present application describes deuterium-enriched saxagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20120035262 - Compositions and methods for lowering triglycerides: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.... Agent: Amarin Pharma, Inc.

20120035263 - Condiment: The present invention relates to a condiment comprising an emulsion of an aqueous phase and an oil or fat phase, the emulsion comprising a potato protein protease inhibitor isolate. The invention further relates to a method for preparing a condiment according to any of the preceding claims, comprising preparing an... Agent:

20120035264 - Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response: Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.... Agent:

20120035265 - Compositions, methods, and devices for the treatment of dysmenorrhea: A method for a prevention and/or treatment of dysmenorrhea or amelioration of a symptom thereof in a subject, comprising administering to said subject an effective amount of a compound of formula I:... Agent: Medicinova, Inc.

20120035266 - Bis(thio-hydrazide amide) salts for treatment of cancers: Disclosed are bis(thio-hydrazide amide) disalts and pharmaceutical compositions thereof. Also disclosed are methods of using bis(thio-hydrazide amide) disalts to treat cancer.... Agent: Synta Pharmaceuticals Corp.

20120035267 - Paracetamol for parenteral adminstration: The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 μS cm−1.... Agent: Fresenius Kabi Deutschland Gmbh

20120035268 - Sphingo-guanidines and their use as inhibitors of sphingosine kinase: The presently disclosed subject matter provides compounds of the formula: (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods for making the compounds of the formula as set forth hereinabove, their use in inhibiting sphingosine... Agent:

20120035269 - Cyclopropene amine compounds: Methods of applying cyclopropene amine derivatives and compositions thereof to inhibit ethylene receptors in plants and plant material are disclosed. Methods include applying to the plant an effective ethylene response-inhibiting amount of at least one cyclopropene amine compound or composition thereof. Cyclopropene amine compounds, enantiomers, stereoisomers or salts thereof are... Agent:

20120035270 - Paediatric solutions comprising a beta-blocker: The present invention relates to aqueous non alcoholic solutions comprising a beta-blocker, a non sugar type sweetener and being substantially free of an aromatic preservative agent. The solutions of the present invention are particularly adapted for a paediatric use.... Agent:

20120035271 - Stereoisomers propofol therapeutic compounds: A (−)-stereoisomer of formula (I): [insert formula (I) wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic.... Agent:

20120035272 - Method to ameliorate oxidative stress and improve working memory via pterostilbene administration: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a... Agent: The United States Of America As Represented By The Secretary Of Agriculture

20120035273 - Pharmaceutical composition comprising glycerol, white soft paraffin and liquid paraffin for the treatment of uremic xerosis and/or pruritus: The invention relates to a pharmaceutical composition comprising a combination of glycerol, white soft paraffin and liquid paraffin as active ingredients for topical use to treat uremic xerosis and/or uremic pruritus.... Agent: Orfagen

20120035274 - Composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients: Disclosed is a composition including camphene as an active ingredient for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome. The composition of the present disclosure including camphene as an active ingredient suppresses differentiation of adipocytes, reduces body fat, reduces visceral fat, reduces total cholesterol level, reduces serum... Agent: Industry-academic Cooperation Foundation, Yonsei University

20120035275 - Emulsion, method for producing the same, and cosmetic raw material formed from the same: The present invention has objectives to provide an emulsion suitable as a cosmetic raw material and to easily obtain the aforementioned emulsion of organopolysiloxane exhibiting superior storage stability. The present invention provides an emulsion comprising (A) an organopolysiloxane, (B) a methyl polyglycerol-modified silicone-based surfactant having a specified structure, and (C)... Agent:

20120035276 - Tissue regenerative composition, method of making, and method of use thereof: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.... Agent:

20120035277 - Liquid-filled chewable supplement: A liquid-filled chewable composition for the oral delivery of nutritional supplements and/or pharmaceuticals is provided. The chewable composition includes a delivery vehicle and an active ingredient incorporated therein. The delivery vehicle may include an organic or non-organic gummy candy including a binding agent, sweetener, flavoring, and/or coloring. The active ingredient... Agent: Hero Nutritionals, LLC

20120035278 - Preparing aminotriazine alkoxylates: The present invention relates to a process for preparing aminotriazine alkoxylates, which comprises at least one aminotriazine alkoxylate (a) being admixed with at least one aminotriazine (b) and reacted with at least one alkylene oxide (c), wherein the aminotriazine alkoxylate (a) is obtainable by reacting at least one aminotriazine (d)... Agent: Basf Se

20120035279 - Protocol for screening travelers: Methods for screening a traveler for an evaluation of the traveler's physical condition or health status by obtaining at least one specimen from the traveler and subjecting the specimen to at least one test that is diagnostic for at least one parameter of the physical condition or health status of... Agent:

  
02/02/2012 > 216 patent applications in 151 patent subcategories. patent applications/inventions, industry category

20120028879 - Highly sensitive detection method for highly virulent oral cavity bacteria: Provided is a method that involves the detection of protein antigen (PA) and/or collagen-binding protein (CBP) of oral cavity bacteria in a sample, and in which oral cavity bacteria that exacerbate hemolysis are detected for and/or subjects at high-risk for hemolysis aggravation are screened anchor the level of risk of... Agent: National University Corporation Hamamatsu University School Of Medicine

20120028878 - Membrane evaporation for generating highly concentrated protein therapeutics: The present invention relates to methods of generating highly concentrated protein solutions, e.g., an antibody solution, a therapeutic protein solution, etc. The methods of the invention include membrane evaporation, such as evaporation of protein-free solvent from the protein solution, which concentrates the protein. The methods of the present invention result... Agent: Wyeth LLC

20120028877 - Self-buffering protein formulations: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the... Agent: Amgen Inc.

20120028880 - Vegfr-1/nrp-1 targeting peptides: The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly D(LPR), that selectively target VEGFR-I and NRP-I expressing cells. Targeted molecules in accor-dance... Agent:

20120028881 - Methods and reagents for diagnosing atheroma: The invention provides a method of diagnosing atheroma in an individual, the method comprising providing a sample from the individual, determining the level of lysozyme in the sample and assessing whether the level is indicative of atheroma in the individual. The invention also provides the use of a reagent which... Agent: Imperial Innovations Limited

20120028882 - Method for removing endotoxin from proteins: Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a... Agent:

20120028883 - Complex and production process: A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of α-lactalbumin, such as human α-lactalbumin or a fragment thereof but which lacks intra-molecular disulfide bonds, and oleic acid, and process for preparing this are described and claimed. The recombinant protein suitably has... Agent: Hamlet Pharma Ab

20120028884 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20120028885 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20120028886 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20120028887 - Lipopeptide inhibitors of hiv-1: The invention provides lipophilic conjugates comprising a short isolated peptide coupled to a hydrophobic moiety, the peptide comprising a sequence derived from the HIV-1 gp41 N-terminal heptad repeat domain, said peptide after conjugation to the hydrophobic moiety possesses anti-fusogenic activity higher than prior to conjugation. The lipophilic conjugates are suitable... Agent: Yeda Research And Development Co. Ltd.

20120028888 - Apj receptor compounds: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ... Agent:

20120028889 - Integrase cofactor: The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules.... Agent: K.u. Leuven Research & Development

20120028890 - Acid containing lipid formulations: The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment... Agent: Camurus Ab

20120028891 - Methods of promoting or maintaining an anabolic state in a female animal: The present invention is related to methods of promoting or maintaining an anabolic state in a female animal. The methods comprise administering a composition to the female animal, with the composition comprising between about 15% to about 25% protein (w/w) and about 5% to about 15% fat (w/w). The protein... Agent: Hill's Pet Nutrition, Inc.

20120028892 - Inhibitors of fructose 1,6-bisphosphatase and methods of use thereof: The invention is directed to a compound according to formula (I). The compounds of formula (I) include prodrugs, pharmaceutically acceptable salts, stereoisomer mixtures, and enantiomers thereof. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier and to methods... Agent: Trustees Of Boston College

20120028893 - Adenovirus 36 e4 orf 1 gene and protein and their uses: Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action... Agent: Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College

20120028895 - Inhibiting serum response factor (srf) to improve glycemic control: Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment.... Agent: Joslin Diabetes Center, Inc.

20120028894 - Peptides, pharmaceutical compositions comprising same and uses thereof: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating... Agent: Ramot At Tel-aviv University Ltd.

20120028896 - Use of fibroblast growth factor fragments: A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention... Agent: Novartis Ag

20120028897 - Methods and compositions for the treatment of fluid retention disorders: Methods of treating fluid retention disorders with the B isomers of guanylin family peptides are described herein. UgnB, when compared to the A isomer (UgnA), exhibits a conventional sigmoidal dose-response relationship in its natriuetic activity. Further, unlike UgnA, UgnB only weakly activates the GC-C receptor. Compositions comprising purified, or mixtures... Agent:

20120028898 - Methods for treatment of headaches by administration of oxytocin: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.... Agent:

20120028899 - Composition and process for synthesizing tense and relaxed state polymerized hemoglobin: Described herein is a composition and process for synthesizing a hemoglobin-based oxygen carrier (HBOC) composition that includes a polymerized hemoglobin locked in at least one of the tense or relaxed quaternary state and has a molecular weight of at least about 500 kDa. The PolyHb may have a cross-linker to... Agent:

20120028900 - Method of producing factor viii proteins by recombinant methods: Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the... Agent:

20120028901 - Tfpi inhibitors and methods of use: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify... Agent: Baxter Healthcare S.a.

20120028902 - Peptide availability: The present invention provides a process for producing a composition which is preferably a food, food intermediate, dietary supplement, feed or pet food, which comprises mixing together a peptide mixture, comprising a bioactive peptide, and a protein source having a protein quality (expressed as PER) of 2.4 or lower. The... Agent:

20120028903 - Modulation of the activity and differentiation of cells expressing the osteoclast-associated receptor: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR... Agent: Cambridge Enterprise Limited

20120028905 - Isolation, purification, and structure elucidation of the antiproliferative compound coibamide a: Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.... Agent: Oregon State

20120028904 - Methods, systems, and compositions for calpain inhabition: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.... Agent: Henry Ford Health System

20120028906 - Method for affecting the timing of cervical ripening and for parturition: A method for affecting the timing of cervical ripening and the resultant onset of parturition in a pregnant female mammal, the method comprises administering to a pregnant female one or more than one dose of an agent that chemically mimics innervation of the cervix by the vagus nerve, thereby advancing... Agent: Loma Linda University

20120028907 - Methods for identification of tumor phenotype and treatment: The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a future date, methods of treating an ERGO tumor in a patient, and methods of selecting patients diagnosed as ERGO tumor... Agent: Intelligent Oncotherapeutics, Inc.

20120028908 - Methods of manufacturing crystalline forms of rapamycin analogs: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin... Agent: Abbott Laboratories

20120028909 - Fn14/trail fusion proteins: Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer,... Agent: The Trustees Of The University Of Pennsylvania

20120028910 - Storage-stable aqueous ophthalmic formulations: Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they... Agent:

20120028911 - Mucin derived polypeptides: The present technology relates to isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same. The MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides can be used to treat gastrointestinal tract diseases and disorders. Also described herein are pharmaceutical compositions comprising MUC17, Muc3 or MUC3 derived polypeptides and/or... Agent: Mucimed, Inc.

20120028912 - Methods of modulating bromodomains: The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease.... Agent: Mount Sinai School Of Medicine

20120028913 - Peptides for inhibiting chemokine binding to chemokine receptors: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective... Agent: Biokine Therapeutics Ltd.

20120028914 - Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum: A pharmaceutical composition including proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of H. pylori from the gastric and duodenal mucosa to be carried out without using wide-spectrum antibiotics. The comprehensive treatment of ulcer disease associated... Agent:

20120028915 - 6\"-amino-6\"-deoxygalactosylceramides: This invention relates to galactosylceramide compounds.... Agent: Brigham Young University

20120028916 - Cosmetic compositions comprising oridonin and new cosmetic uses: The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of... Agent: Sederma

20120028917 - Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistant cancer: The present invention relates to methods of using the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl) -1-phthalazinamine, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and/or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes methods of treating cancers... Agent: Amgen Inc.

20120029049 - Antisense modulation of superoxide dismutase 1, soluble expression: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of... Agent: Isis Corporation

20120029057 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20120029058 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20120029059 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20120029060 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20120029050 - Compositions and their uses directed to diacylglycerol acyltransferase 1: Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a... Agent: Isis Pharmaceuticals, Inc.

20120029056 - Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjÖgren's syndrome: The identification of differentially expressed microRNAs in patients with Sjögren's syndrome is disclosed herein. Provided is a method of diagnosing a subject as having Sjögren's syndrome by measuring the level of at least one differentially expressed miR gene product identified herein. An alteration in the level of the at least... Agent:

20120029055 - Modulators of apoptosis and the uses thereof: Here we demonstrate that miR-125b, a brain-enriched microRNA, is a negative regulator of p53 in animals. miR-125b-mediated downregulation of p53 is dependent on the binding of miR-125b to a microRNA response element in the 39 untranslated region of p53 mRNA. Overexpression of miR-125b represses the endogenous level of p53 protein... Agent: Agecy For Science, Technology And Research

20120029054 - Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of GATA3 gene expression and/or activity, and/or modulate a GATA3 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp.

20120029052 - Short interfering ribonucleic acid (sirna) for oral administration: Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.... Agent: Novartis Ag

20120029053 - Short interfering ribonucleic acid (sirna) for oral administration: Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.... Agent: Novartis Ag

20120029051 - Sirna targeting vegfa and methods for treatment in vivo: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic... Agent: Dharmacon, Inc.

20120029063 - Chimeric nk receptor and methods for treating cancer: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are... Agent: Trustees Of Dartmouth College

20120029062 - Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof: Provided herein are nanoparticle platforms and combinatorial drug delivery vehicles comprising gold nanoparticles with a plurality of thilolated hyperbranched dendrons conjugated to the nanoparticle surface. The thiolated hyperbranched dendrons comprise chemically-modifiable surface groups, functionalized interior groups and nano-cavities within the hyperbranched structure to which a variety of payload molecules may... Agent:

20120029061 - Rna sequence-specific mediators of rna interference: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long... Agent:

20120028918 - Pharmaceutical compositions and methods of making same: The present invention relates to pharmaceutical compositions that include about 10 mg pazopanib/mL of the composition and about 2 to about 13% w/w of a modified cyclodextrin as well as methods of making the same are described.... Agent: Glaxo Wellcome Manufacturing Pte Ltd.

20120028920 - Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders: e

20120028919 - Pyrrolotriazines as alk and jak2 inhibitors:

20120028921 - Methods and compositions using oxidized phospholipids: The instant invention provides compositions, e.g., compositions comprising oxidized phospholipids, for the treatment of diseases, disorders and conditions, e.g., cute lung injury syndromes, sepsis, vascular leakage, edema, acute respiratory distress syndrome (ARDS) or acute inflammation.... Agent: The Johns Hopkins University

20120028922 - Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.... Agent:

20120028924 - Chemical compounds: p

20120028923 - Compositions and methods for inhibition of the jak pathway: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the... Agent: Rigel Pharmaceuticals, Inc.

20120028925 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Abbott Laboratories

20120028926 - Phosphate management with small molecules: This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.... Agent: Cytochroma Inc.

20120028927 - Novel triazene compounds for the treatment of cancer: The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at... Agent: Trin Therapeutics Gmbh

20120028928 - Process for isolating tigecycline and tigecycline made therefrom: The present invention provides a process for isolating tigecycline which process comprises the step of spray drying a solution of tigecycline in a solvent. Preferably the solvent is water or an organic solvent. In another aspect, there is provided tigecycline obtainable by spray drying, particularly in amorphous form. In particular,... Agent: Hovione Inter Limited

20120028929 - Tetracycline stabilizing formulations: An aqueous solution comprising a chelating agent at a concentration of about 0.1-0.5%, and an antioxidant agent at a concentration of about 0.1-0.5%, wherein the pH of the solution is between about 4.5 and about 7.5 is disclosed. The aqueous solution may comprise a tetracycline composition wherein the tetracycline is... Agent: Alacrity Bioscience, Inc.

20120028930 - Flupirtine salts and polymorphs: The present invention includes salts and polymorphs of flupirtine including, but not limited to carboxylic acid salts and sulfonic acid salts and their polymorphs. The present invention also includes pharmaceutical compositions comprising the salts and polymorphs of flupirtine. The invention also relates to the therapeutic use of the flupirtine salts... Agent: Bionevia Pharmaceuticals Inc.

20120028932 - Drug combinations containing pde4 inhibitors and nsaids: e

20120028931 - Heterocyclic m-glu5 antagonists: and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful for the treatment of neuromuscular dysfunction of the lower urinary tract and also for the treatment of gastrooesophageal reflux disease; anxiety disorder; abuse, substance dependence and substance withdrawal disorders; neuropathic pain disorder, migraine and... Agent: Recordati Ireland Limited

20120028933 - Cell culture media supplement and method of molecular stress control: A novel class of agents has been identified to serve as cell-guard agents and/or target-specific supplements to increase cell quality and yield, as well as select for target cell populations. Laboratory experiments have demonstrated the use of cell-guard agents and/or target-specific supplements in the bioprocessing of cells as well as... Agent:

20120028934 - Stable pharmacologically active compositions including vitamin d-containing and corticosteroid compounds with low ph compatibility: Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of... Agent:

20120028936 - Oral contraception with trimegestone: The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone... Agent: Grunenthal Gmbh

20120028935 - Therapeutic gestagens for the treatment of premenstrual dysphoric disorder: A method of treating premenstrual dysphoric disorders comprising administering to a patient in need of such treatment daily from day 1 to day 24 3 mg of drospirenone and 0.02 mg of ethinylestradiol.... Agent:

20120028937 - Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same: Provided is a compound useful as a therapeutic drug for pain and inflammation caused by various pathological conditions such as neuropathic pain and rheumatoid arthritis. The compound of the formula (I) or a salt thereof [wherein R1 is a methyl group or a hydrogen atom, R2 represents a hydrogen atom,... Agent:

20120028940 - Functionally selective azanitrile alpha-2c adrenoreceptor agonists: In its many embodiments, the present invention provides a novel class of azanitrile compounds as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention,... Agent: Merck Sharp & Dohme Corp.

20120028943 - Medicinal cream made using fluticasone propionate and chitosan and a process to make the same: The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form... Agent: Apex Laboratories Private Limited

20120028942 - Medicinal cream made using neomycin sulphate, betamethasone valerate, and chitosan, and a process to make the same: The present invention is directed to a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antibacterial active ingredient. It discloses a composition for treating bacterial skin infections &... Agent: Apex Laboratories Private Limited

20120028941 - Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclopropyl-3-fluoro-4-methyl-5[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a β2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a... Agent:

20120028938 - Pyrazole compounds as crth2 antagonists: e

20120028939 - Substituted naphthyridines and their use as medicaments:

20120028944 - Cyclodextrin nanotechnology for ophthalmic drug delivery: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of... Agent: Oculis Ehf

20120028945 - 5-beta, 14-beta-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure: Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of proteinuria, glomerulosclerosis or renal failure.... Agent:

20120028946 - Testosterone gel and method of use: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.... Agent:

20120028947 - Ophthalmic compositions: An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid. The composition has a viscosity in the range from about 300 cp to about 1500 cp, and a total concentration of cations of less than about 50 mM. The ophthalmic composition is used to treat patients suffering from allergic conjunctivitis,... Agent:

20120028948 - Testosterone gel and method of use: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.... Agent:

20120028949 - Rapidly disintegrating tablet: The present invention relates to rapidly disintegrating tablets intended to be used as orodispersible tablets or dispersible tablets. They are ingested either by dispersing directly in the mouth or in water. The tablets include silicified microsrystalline cellulose. They are especially suitable for antibiotics. These tablets are also suitable for use... Agent:

20120028951 - Pyridazinone compounds: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen... Agent: Takeda Pharmaceutical Company Limited

20120028952 - 5-alkynyl-pyrimidines: e

20120028953 - Azetidine derivatives: Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Formula (I) Wherein Ar1 is optionally... Agent: Vernalis (r&d) Ltd.

20120028954 - Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same: m

20120028950 - Substituted heterocyclylbenzylpyrazoles and use thereof: The present application relates to novel substituted 1-[3-(heterocyclyl)benzyl]-1H-pyrazole derivatives, to processes for preparation thereof, to use thereof for treatment and/or prevention of diseases and to use thereof for production of medicaments for treatment and/or prevention of diseases, more particularly for treatment and/or prevention of hyperproliferative and angiogenic diseases and those... Agent: Bayer Schering Pharma Aktiengesellschaft

20120028955 - Bicyclic mglur5 positive allosteric modulators and methods of making and using same: In one aspect, the invention relates to bicyclic mGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating... Agent:

20120028956 - Bicyclic mglur5 positive allosteric modulators and methods of making and using same: In one aspect, the invention relates to bicyclic mGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating... Agent:

20120028957 - Inhibitors of the influenza a virus m2 proton channel: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being... Agent:

20120028958 - 5-alkynyl-pyrimidines: o

20120028959 - Dihydroorotate dehydrogenase inhibitors: The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.... Agent: Merck Serono S.a.

20120028960 - Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug... Agent:

20120028961 - 6 substituted 2, 3,4,5 tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonist: p

20120028962 - Fused heterocyclic ring compound:

20120028963 - Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same: The present invention relates to hydroxamate derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the compositions, and a method for preparing the hydroxamate derivatives.... Agent: Chong Kun Dang Pharmaceutical Corp.

20120028964 - Pharmaceutical combination: The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, which comprises a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist) and an antipsychotic drug. This combination can reduce metabolic side effects which appear if... Agent:

20120028965 - Compounds useful as protein kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20120028967 - Novel diaza-bicyclononyl-pyrimidinyl derivatives and their medical use: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the... Agent: Neurosearch A/s

20120028968 - Novel dibenzofuranyl-oxadiazolyl-diazabicyclononane derivatives and their medical use: This invention relates to novel dibenzofuranyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention... Agent: Neurosearch A/s

20120028966 - Protein kinase inhibitors: i

20120028969 - Bicyclic acetyl-coa carboxylase inhibitors and uses thereof:

20120028970 - Heteroarylthiomethyl pyridine derivative: The present invention relates to a compound represented by a formula (I): wherein X is a group represented by or the like; Y is a group represented by or the like; and Ar1 is a group represented by or a pharmaceutically acceptable salt thereof.... Agent: Msd K.k.

20120028971 - Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof: The present application relates to novel alkylcarboxylic acids having an oxo-substituted azaheterocyclic partial structure, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of... Agent: Bayer Pharma Aktiengesellschaft

20120028972 - Biomarker assays for detecting or measuring inhibition of tor kinase activity: Provided herein are methods for detecting and/or measuring the inhibition of TOR kinase activity in a subject and uses associated therewith.... Agent:

20120028973 - Nitroimidazooxazines and their uses in anti-tubercular therapy: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.... Agent: Global Alliance For Tb Drug Development

20120028975 - Substituted triazolopyridines and analogs thereof: The present invention relates to substituted triazolopyridines and analogs thereof, the use of the compounds as phosphodiesterase 10 (PDE10) inhibitors for the treatment of PDE10-modulated disorders, to pharmaceutical compositions comprising the compounds.... Agent:

20120028974 - Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases: The present invention relates to a compound according to formula I, wherein R1, R2 and A are as defined herein, which exhibit PDE4 inhibitory activity and may be used in the treatment of inflammatory diseases or autoimmune diseases, in particular inflammatory or proliferative dermal diseases.... Agent: Leo Pharma A/s

20120028976 - Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist: Dosing regimens based on the pharmacokinetic characteristics of a thrombin receptor antagonist are disclosed. In some embodiments, the dosing regimens result in mean plasma concentrations. Also disclosed are methods of treating acute coronary syndrome and peripheral arterial disease, and of effecting secondary prevention, by orally administering thrombin receptor antagonists according... Agent:

20120028977 - Subunit selective nmda receptor potentiators for the treatment of neurological conditions: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or... Agent: Emory University

20120028979 - 2-(piperidin-1-yl)-4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent:

20120028978 - Substituted bicyclic hcv inhibitors: Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.... Agent: Presidio Pharmaceuticals, Inc.

20120028980 - Use of nk-1 receptor antagonists in management of visceral pain: Methods for managing visceral pain in mammalian subjects are described, in which a NK-1 receptor antagonist is administered to the subject before, during or after administration of general anesthesia. The methods and uses of NK-1 receptor antagonists described herein provide improved visceral pain management and MAC reduction when used with... Agent: Colorado State University

20120028981 - Kinase knockdown via electrophilically enhanced inhibitors: Provided herein are electrophilically enhanced kinase inhibitors. Also provided herein are methods of making and utilizing the same.... Agent: Principia Biopharma Inc.

20120028982 - 2-amino-bicyclo[3.1.0]hexane-2, 6-dicarboxylic ester derivative: [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a... Agent: Taisho Pharmaceutical Co., Ltd.

20120028983 - Novel compound having 3-heteroarylpyrimidin-4-(3h)-one structure and pharmaceutical preparation containing same: Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications,... Agent: Kowa Company, Ltd.

20120028984 - Compound useful as a c-met inhibitor: The present invention relates to a c-Met inhibitor (disclosed herein) or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors.... Agent: Eli Lilly And Company

20120028985 - Combinational therapy for treating autoimmune disease: The present invention relates to the treatment and prevention of immunological and inflammatory disorders with a compound of formula (I) in combination with methotrexate,... Agent: 4sc Ag

20120028986 - 2-heteroaryl-pyrrolo [3,4-c]pyrrole derivatives, and use thereof as scd inhibitors: The invention relates to compounds of the formula (I), where the groups R1, M, A, B, D, L, and R have the specified meanings, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treating metabolic syndrome, insulin resistance, obesity, and diabetes.... Agent: Sanofi-aventis

20120028987 - Bicyclic benzamides of 3-or-4-substituted 4-(aminomethyl)-piperidine derivatives: e

20120028988 - Use of pyridazinone compound for control of harmful arthropod pests: Since a pyridazinone compound shown by formula (I) has an activity for controlling arthropod pests, the pyridazinone compound is effective for a use for controlling arthropod pests.... Agent: Sumitomo Chemical Company, Limited

20120028989 - 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines: The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.... Agent:

20120028990 - 3 aryl or heteroaryl-substituted indole derivative: A 3-aryl or heteroaryl-substituted indole derivative which is effective as a preventive or remedy for various diseases is provided. [Means for Resolution] A compound represented by a formula (I) or a pharmaceutically acceptable salt thereof is provided. In the formula, R1 represents a hydrogen atom, C1-6 alkyl et al; R2... Agent: Msd K.k

20120028991 - Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands: The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of... Agent: Forest Laboratories Holdings Ltd.

20120028993 - Compounds effective against cancer: The present invention describes a Composition, comprising one or more compounds selected from the group consisting of a) compound (I) which is ethacrynic acid bezafibrate, fenofibrate, and/or griseofulvin, b) compound (II), which is ciclopirox ciclopirox olamine, octopirox, and/or cinnarizine, c) mixtures of compound (I) and compound (II), or pharmaceutically acceptable... Agent:

20120028992 - Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals: Disclosed are pharmaceutical compositions for and methods of preventing or treating acute and/or chronic cardiac arrhythmias in a mammal, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm, which contain a combination of 1-[2-[(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.... Agent:

20120028994 - Compounds for the reduction of beta-amyloid production: s

20120028995 - Novel compounds for medical use as peptidase effectors: The invention relates to compounds of general formula (I) as set forth in the claims as well as to the use of the compounds of the general formula (1) in the medical field, specifically for use in the suppression of DNA synthesis and inflammatory cytokine production as well as in... Agent: Imtm Gmbh

20120028996 - Novel oxime derivatives: The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.... Agent: Cadila Healthcare Limited

20120028997 - Prokineticin 1 receptor antagonists: e

20120028999 - Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus: This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention... Agent: Anadys Pharmaceuticals, Inc.

20120028998 - Co-crystal of etravirine and nicotinamide: Etravirine (TMC125) nicotinamide co-crystal, its preparation, and use in the treatment of HIV infection.... Agent:

20120029000 - Process for the preparation of alogliptin: The present invention is based on the discovery of a process for preparing pyrimidin-dione compounds, especially alogliptin and its derivatives, which comprises the reaction of a urea derivative of formula (VIII) with a malonic acid or its derivatives to form intermediates of formulae (VII) or (VII-A), which are subsequently converted... Agent: Mapi Pharma Limited

20120029002 - Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases: The present application relates to novel fused, heteroatom-bridged pyrazole and imidazole derivatives, to processes for their preparation, to their use, alone or in combination, for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment... Agent: Bayer Schering Pharma Aktiengesellschaft

20120029003 - Galectin-3 and statin therapy: Described herein are materials and methods for predicting and monitoring a heart failure patient's physiological response to treatment with a statin. More specifically, the present invention relates to the endogenous protein galectin-3 and its use as a predictor of response to treatment with 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, or statins.... Agent: Bg Medicine, Inc.

20120029001 - Method of treatment of nephrogenic diabetes insipidus: Nephrogenic diabetes insipidus is treated with statins.... Agent: Universita' Degli Studi Di Bar (italian Nationality)

20120029004 - Novel aminopyridine derivatives having aurora a selective inhibitory action: The present invention relates to a compound of Formula (I): wherein: R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected... Agent:

20120029006 - Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine compounds: Cis-tetrahydro-spiro(cyclohexane-1,1′-pyrido[3,4-b]indole)-4-amine compounds which act on the nociceptin/ORL-1 receptor system as well as on the μ-opioid receptor system and which are distinguished in particular by selective effectiveness in the treatment of chronic pain, such as inflammatory pain, visceral pain, tumour pain, and neuropathic pain, without at the same time developing pronounced... Agent: Gruenenthal Gmbh

20120029005 - Spiperone derivatives and methods of treating disorders: Described herein are spiperone derivative compounds which have been found to be useful in methods of stimulating CaCC and treating disorders (or symptoms thereof) associated with CaCC including cystic fibrosis, wherein a compound of the invention is administered to a subject.... Agent: The Johns Hopkins University

20120029008 - Crystalline and amorphous forms of nalbuphine hydrochloride: The present invention is directed to novel crystalline and amorphous forms of nalbuphine hydrochloride.... Agent:

20120029007 - Morphinan compounds: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA... Agent:

20120029009 - Tacrolimus for improved treatment of transplant patients: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It... Agent: Lifecycle Pharma A/s

20120029010 - Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter: The sponges were collected from a variety of locations in the Florida Keys and separated based on morphology and color. The samples were identified as three species, two of which are well known: V. rigida (Esper, 1794) (order Verongida, family Aplysinidae) and S. aurea (Hyatt, 1875) (order Dictyoceratida, family Thorectidae),... Agent:

20120029011 - Novel nitrogen-containing heteroaryl compounds and methods of use thereof: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.... Agent: Fibrogen, Inc.

20120029012 - 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof: The present invention relates to 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives represented by general formula D, their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disorders by administering the compounds are also included.... Agent: Rexahn Pharmaceuticals, Inc.

20120029013 - Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products: The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C1-C6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the... Agent: Pierre Fabre Medicament

20120029014 - 5-(2--1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function: e

20120029015 - Novel medical use of kynurenic acid, its precursors and derivatives: In the most preferred embodiment, the invention concerns the use of kynurenic acid or its pharmaceutically acceptable salt in manufacturing of a drug used in prevention and therapy of pancreas disorders characterized by edema and/or vacuolization and/or destruction of pancreatic tissue and/or pancreas necrosis leading to release of pancreatic α-amylase.... Agent:

20120029016 - Indoles useful in the treatment of inflammation: There is provided compounds of formula I, wherein ring R1a to R1c, R2a to R2e, and X have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in... Agent: Biolipox Ab

20120029017 - Pectin-containing jelly formulation: There is disclosed a technique for making a jelly formulation comprising pectin slide out of a container easily (improving the slidability of the jelly formulation) when taking the formulation out of the container to prevent the formulation from remaining in the container. The jelly formulation of the present invention comprises... Agent: Nichi-iko Pharma Factory Co., Ltd.

20120029018 - 9-substituted phenanthrene based tylophorine derivatives: The present invention provides compounds of Formula I: compositions containing the same, and methods of use thereof such as for the treatment of cancer.... Agent:

20120029019 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Celgene Corporation

20120029020 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Celgene Corporation

20120029021 - Nitroxide free radical synergized antineoplastic agents: Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the... Agent: The Trustees Of California State University

20120029022 - Potent non-urea inhibitors of soluble epoxide hydrolase: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or... Agent: The Trustees Of Columbia Univesity In The City Of New York

20120029023 - Heterocycles substituted pyridine derivatives and antifungal agent containing thereof: e

20120029024 - Spot-on pesticide composition: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation... Agent: Sergeant's Pet Care Products, Inc.

20120029025 - Spot-on pesticide composition: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation... Agent: Sergeant's Pet Care Products, Inc.

20120029026 - Pyridine derivative: [wherein R represents a pyridyl group substituted with 1 to 3 group(s) independently selected from Substituent Group A, and Substituent Group A represents a halogen atom, a C1-C6 alkyl group and a C1-C6 alkoxy group] or a pharmacologically acceptable ester thereof, or a pharmacologically acceptable salt of the compound or... Agent: Daiichi Sankyo Company, Limited

20120029027 - N-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide derivatives, preparation thereof, and therapeutic use of same: The invention relates to a compound of the general formula (I), where: R is a hydrogen atom or a group selected from the (C1-C6)alkyl or (C3-C7)-cycloalkyl groups, optionally substituted by one or more groups independently selected from a halogen atom anti the (C3-C7)-cycloalkyl, (C1-C6)alkyl, (C1-C6)alkoxy, and hydroxy groups; R1 is... Agent: Sanofi

20120029028 - Compositions and methods for treating hyperlipidemias: The present invention is directed to a composition and method for the treatment of hyperlipidemias by targeting Microsomal triglyceride transfer protein (MTP). In particular, the present invention is directed to a combination of at least one MTP inhibitor and at least one lipid-lowering agent, both in an amount effective to... Agent: The Research Foundation Of State University Of New York

20120029030 - Method for customized dispensing of variable dose drug combination products for individualizing of therapies: Generally the method involves identifying the concentration of each of two or more active therapeutics tailored to treat a particular patient's unique metabolism and one or more diseases, communicating that information to a producer who has multiple fixed or variable concentrations of each active available, where the producer then combines... Agent: Smithkline Beecham Corporation

20120029029 - Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators: The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also... Agent: High Point Pharmaceuticals, LLC

20120029031 - Metadoxine for use as inhibitor of hepatic fibrosis: The use of metadoxine in the treatment of hepatic fibrosis is described. Metadoxine can be orally and/or parenterally administered at a dosage comprised between 50 and 1000 mg per dose, preferably between 300 and 600 mg per dose. In the in vitro study, metadoxine results effective at lower concentrations with... Agent: Laboratori Baldacci Spa

20120029032 - Matrix-type sustained release preparation containing basic additive: Disclosed is a matrix-type sustained release preparation containing a basic drug unstable against an acid as an active pharmaceutical ingredient, wherein the decomposition of the basic drug unstable against the acid can be prevented and therefore the pH-dependent release can be reduced. A hardly water-soluble basic normal salt is added... Agent: Kyorin Pharmaceutical Co., Ltd.

20120029033 - Spot-on pesticide composition: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation... Agent: Sergeant's Pet Care Products, Inc.

20120029034 - Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents: s

20120029035 - Compositions and methods for extended therapy with aminopyridines: Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.... Agent: Acorda Therapeutics, Inc.

20120029036 - Pharmaceutical compositions comprising pyridyl cyanoguanidine, process for preparing the same and use thereof: Disclosed are a composition comprising a pyridyl cyanoguanidine and a cyclodextrin, a cyclodextrin derivative and/or a surfactant with solubilization, process for preparing the same and use thereof.... Agent: Tianjin Hemay Bio-tech Co., Ltd.

20120029037 - Animal ectoparasite-controlling agent: wherein R3 represents a fluorine atom, a chlorine atom, a bromine atom, a methyl group, an ethyl group or a hydrogen atom, R5 and R6 are the same or different each other and each represents a methyl group or a hydrogen atom, R4 represents a C1-C6 alkyl group, which shows... Agent: Sumitomo Chemical Company, Limited

20120029038 - Animal ectoparasite-controlling agent: wherein R3 represents a fluorine atom, a chlorine atom, a bromine atom, a methyl group, an ethyl group or a hydrogen atom, R5 and R6 are the same or different each other and each represents a methyl group or a hydrogen atom, R4 represents a C1-C6 haloalkyl group, which shows... Agent: Sumitomo Chemical Company, Limited

20120029039 - Animal ectoparasite-controlling agent: wherein R3 represents a fluorine atom, a chlorine atom, a bromine atom, a methyl group, an ethyl group or a hydrogen atom, R5 and R6 are the same or different each other and each represents a methyl group or a hydrogen atom, R4 represents a C1-C6 alkyl group substituted by... Agent:

20120029040 - Animal ectoparasite-controlling agent: wherein R3 represents a fluorine atom, a chlorine atom, a bromine atom, a methyl group, an ethyl group or a hydrogen atom, R5 and R6 are the same or different each other and each represents a methyl group or a hydrogen atom, R4 represents a C3-C6 cycloalkyl group, which shows... Agent:

20120029041 - 2-aryl imidazoline derivatives: 2-Aryl imidazoline derivatives are provided that are useful as anti-obesity agents or the like. A compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a hydrogen atom, halogen, C1-6alkyl, or the like; R3a, R3b, R4a and R4b each independently represent a... Agent: Msd K.k.

20120029042 - Clonidine for treatment of bone cancer: The present invention is directed to a method for treating osteolytic bone cancer. The method comprises implanting a drug depot locally at or near the osteolytic bone cancer, wherein the drug depot comprises at least one biodegradable polymer and clonidine in an amount from about 0.1 wt. % to about... Agent: Warsaw Orthopedic, Inc.

20120029043 - Pharmaceutical composition containing an n-phenylpyrazole derivative, and use thereof for preparing a topical veterinary for flea control: The invention relates to a liquid pharmaceutical composition that contains an N-phenylpyrazole derivative as an active principle, benzyl alcohol, and an appropriately selected organic solvent, and to the use of such a composition for preparing a topically applied antiparasitic veterinary drug for preventing and/or treating flea infestation in pets, in... Agent:

20120029044 - 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.... Agent:

20120029045 - Method for treating port wine stains: A method of using photodynamic therapy to perform selective targeted therapy of biological tissue. The method includes intravenously injecting a porphyrin-based photosensitizing drug followed by irradiating the tissue with light while the drug is being injected. The duration of the irradiation and other parameters are controlled so that the selected... Agent: Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.

20120029046 - Crystalline form of sunitinib and processes for its preparation: The present invention relates to a novel crystalline form of sunitinib free base designated form I and to processes for its preparation. The invention also relates to its use as an API and in the preparation of various forms of sunitinib. Further, the invention relates to pharmaceutical compositions comprising the... Agent: Generics (uk) Limited

20120029047 - Use of hdac inhibitors for the treatment of bone destruction: The present invention relates to the use of HDAC inhibitors for the treatment of bone destruction caused by cancer, inflammatory diseases and osteoporosis.... Agent:

20120029048 - Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies: The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies and compositions for this use.... Agent: Via Pharmaceuticals, Inc.

20120029064 - formulation of silibinin with high efficacy and prolonged action and the preparation method thereof: A high-efficacy, long-acting formulation of silibinin, comprising silibinin solid dispersion, silibinin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silibinin solid dispersion:silibinin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silibinin-loaded silica nanoparticles is 51.29˜51.77%; the said silibinin... Agent: Jiangsu University

20120029065 - Compositions for treating or preventing obesity and insulin resistance disorders: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or... Agent: President And Fellows Of Harvard College

20120029067 - Polyphenol proteasome inhibitors, synthesis, and methods of use: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.... Agent: Mcgill University

20120029066 - Use of flavones for treating psychiatric disorders with sensorimotor gating deficits: Novel Use of flavones having 2-phenylchromen-4-one skeleton is disclosed herein. The flavones are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating a patient diagnosed with a psychiatric disorder with sensorimotor gating deficits.... Agent: National Taiwan University

20120029068 - Transdermal fluid: The present invention relates to a transdermal fluid. The transdermal fluid containing an active amount of a tocotrienol is described, useful for the treatment or prevention of a cancer or a tumour or an inflammatory disorder, particularly breast cancer. The fluid can be used either in combination with known medication... Agent: Malaysian Palm Oil Broard A/k/a Mpob

20120029069 - Compound extracted from antrodia cinnamomea and pharmaceutical composition comprising the same: This invention relates to a novel compound extracted from antrodia Cinnamomea and related compounds of formula (1), and pharmaceutical compositions comprising the compound of formula (1) and a pharmaceutically acceptable carrier or excipient. The invention further comprises the method of inhibit cancer cells by administering an effective amount of the... Agent:

20120029070 - Burdock fruit extract containing arctigenin at high content and process for producing same: i

20120029071 - Compositions and methods for treating or preventing radiation injury: The invention provides compositions and methods featuring Nrf2 activators for treating or preventing radiation-associated tissue damage.... Agent: The Johns Hopkins University

20120029072 - Pleuromutilin derivatives for the treatment of diseases mediated by microbes: e

20120029073 - Pharmaceutical compositions having desirable bioavailability: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as... Agent:

20120029074 - Controlling transgene expression across the skin: The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of the Pseudomonas putida DOT-T1E-derived bacterial repressor TtgR, to a vector comprising the genetic code for the repressor TtgR fused to a transactivation or a transrepressor domain, to a vector... Agent:

20120029075 - Compositions containing c1 to c7 organic acid monoglycerides and glycerol, their preparation and use as antibacterials and anti-mould agents: Described are antibacterial and anti-mould compositions containing high amounts of C1 to C7 organic acid mono-glycerides and glycerol, their preparation and their use in animal feedstuffs.... Agent:

20120029076 - Micronized polymer powder and cosmetic composition thereof: s

20120029077 - Animal feed additive and animal feed comprising alkyl esters of medium chain fatty acids, and their use in animal feed: The invention is directed to an animal feed suitable for feeding mammals, birds and fish, comprising an alkyl ester of a fatty acid, wherein said fatty acid has a chain length of 5-12 carbon atoms, and wherein the dosage of said ester in said animal feed is 50 ppm by... Agent:

20120029078 - Compositions comprising myristic acid and uses thereof: The teachings herein are directed to antibacterial and anti-inflammatory pharmaceutical compositions that include myristic acid. Further embodiments herein are directed to methods of administering sufficient amounts of myristic compositions to patients in need thereof in order to prevent or treat inflammation and/or bacterial infection. Myristic acid has been established to... Agent: Imagenetix, Inc.

20120029079 - Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids: The molecules of formula (I) are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipis of eicosanoid status or functions may be desirable. Formula (I): Z1—Z1—Z2 wherein a) Z1 represents CO2H or a derivative thereof; b) Z2 represents F, H, —CO2H or... Agent: Cxr Biosciences Limited

20120029080 - Reduction of risk of obesity: A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance... Agent: Nestec S.a.

20120029081 - Solid pharmaceutical compositions containing pregabalin: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.... Agent: Warner-lambert Company LLC

20120029082 - Nutritional or therapeutic compositions to increase bodily glutathione levels: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.... Agent:

20120029083 - Polymorphic forms of aliskiren hemifumarate and process for preparation thereof: Provided are amorphous and polymorphic forms of aliskiren hemifumarate, pharmaceutical compositions thereof, and processes for their preparation.... Agent: Teva Pharmaceutical Industries, Ltd.

20120029084 - Topical nepafenac formulations: Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.... Agent: Novartis Ag

20120029085 - Stabilization of quinol composition such as catecholamine drugs: Compositions and methods are provided for obtaining stabilized quinol compositions, such as catecholamine drugs (e.g., epinephrine solutions), and also for obtaining stable pharmaceutical formulations that comprise a stabilized quinol composition and a second pharmacologically active component such as a local anesthetic or other active drug ingredient having a reversibly protonated... Agent:

20120029086 - Compositions and method for temporary reduction of nasal and sinus pain: Compositions and method that are expedient, safe, non-habit forming, and non-sedating for temporary reduction of nasal and sinus pain comprised of a local anesthetic or local anesthetics in a pharmaceutically acceptable carrier by instillation into the nasal cavity and sinuses by method of nasal spray.... Agent:

20120029087 - Use of rasagiline for the treatment of olfactory dysfunction: Disclosed are methods of treating olfactory dysfunction by periodically administering a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to a subject.... Agent:

20120029088 - Anti-anxiety composition: This invention provides a highly safe anti-anxiety composition that can be used for treatment or prevention of anxiety disorders. Such anti-anxiety composition comprises, as an active ingredient, a carotenoid.... Agent: Jx Nippon Oil & Energy Corporation

20120029089 - Preparing biodegradable hydrogel for biomedical application: Biodegradable dextran based hydrogel suitable for biomedical application is produced by subjecting polysaccharide substituted with unsaturated moiety, e.g. dextran methacrylate, in aqueous medium to UV or visible light irradiation in the precense of riboflavin/L-arginine or riboflavin/chitosan to cause photocrosslinking of polysaccharide substituted with unsaturated moiety.... Agent:

20120029090 - Modified alkoxylation products having at least one non-terminal alkoxysilyl group, with increased storage life and increased stretchability of the polymers prepared using them: Modified alkoxylation products of the formula (I), their use and processes for preparing them... Agent: Evonik Goldschmidt Gmbh

20120029091 - Method of controlling the release of an active ingredient from a dosage form: d

20120029092 - Product containing diamides, method for making same and uses thereof:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141113: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.38688 seconds

PATENT INFO